1
|
Zarka D, Cevallos C, Ruiz P, Petieau M, Cebolla AM, Bengoetxea A, Cheron G. Electroencephalography microstates highlight specific mindfulness traits. Eur J Neurosci 2024; 59:1753-1769. [PMID: 38221503 DOI: 10.1111/ejn.16247] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 09/06/2023] [Revised: 11/29/2023] [Accepted: 12/18/2023] [Indexed: 01/16/2024]
Abstract
The present study aimed to investigate the spontaneous dynamics of large-scale brain networks underlying mindfulness as a dispositional trait, through resting-state electroencephalography (EEG) microstates analysis. Eighteen participants had attended a standardized mindfulness-based stress reduction training (MBSR), and 18 matched waitlist individuals (CTRL) were recorded at rest while they were passively exposed to auditory stimuli. Participants' mindfulness traits were assessed with the Five Facet Mindfulness Questionnaire (FFMQ). To further explore the relationship between microstate dynamics at rest and mindfulness traits, participants were also asked to rate their experience according to five phenomenal dimensions. After training, MBSR participants showed a highly significant increase in FFMQ score, as well as higher observing and non-reactivity FFMQ sub-scores than CTRL participants. Microstate analysis revealed four classes of microstates (A-D) in global clustering across all subjects. The MBSR group showed lower duration, occurrence and coverage of microstate C than the control group. Moreover, these microstate C parameters were negatively correlated to non-reactivity sub-scores of FFMQ across participants, whereas the microstate A occurrence was negatively correlated to FFMQ total score. Further analysis of participants' self-reports suggested that MBSR participants showed a better sensory-affective integration of auditory interferences. In line with previous studies, our results suggest that temporal dynamics of microstate C underlie specifically the non-reactivity trait of mindfulness. These findings encourage further research into microstates in the evaluation and monitoring of the impact of mindfulness-based interventions on the mental health and well-being of individuals.
Collapse
Affiliation(s)
- D Zarka
- Laboratory of Neurophysiology and Movement Biomechanics, Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
- Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
| | - C Cevallos
- Laboratory of Neurophysiology and Movement Biomechanics, Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
- Departamento de Ingeniería Mecánica, Facultad de Ingeniería Mecánica, Escuela Politécnica Nacional, Quito, Ecuador
| | - P Ruiz
- Departamento de Ingeniería Mecánica, Facultad de Ingeniería Mecánica, Escuela Politécnica Nacional, Quito, Ecuador
| | - M Petieau
- Laboratory of Neurophysiology and Movement Biomechanics, Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
| | - A M Cebolla
- Laboratory of Neurophysiology and Movement Biomechanics, Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
| | - A Bengoetxea
- Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
- Athenea Neuroclinics, San Sebastian, Spain
| | - G Cheron
- Laboratory of Neurophysiology and Movement Biomechanics, Research Unit in Sciences of Osteopathy, Faculty of Human Motor Sciences, Université Libre de Bruxelles, Brussels, Belgium
- Laboratory of Electrophysiology, Université de Mons, Mons, Belgium
| |
Collapse
|
2
|
Martinez-Gzegozewska Y, Rasmussen L, McKellip S, Manuvakhova A, Nebane NM, Reece AJ, Ruiz P, Sosa M, Bostwick R, Vinson P. High-Throughput cell-based immunofluorescence assays against influenza. SLAS Discov 2024; 29:66-76. [PMID: 37925159 DOI: 10.1016/j.slasd.2023.10.008] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 08/10/2023] [Revised: 10/19/2023] [Accepted: 10/30/2023] [Indexed: 11/06/2023]
Abstract
A rapid drug discovery response to influenza outbreaks with the potential to reach pandemic status could help minimize the virus's impact by reducing the time to identify anti-influenza drugs. Although several anti-influenza strategies have been considered in the search for new drugs, only a few therapeutic agents are approved for clinical use. The cytopathic effect induced by the influenza virus in Madin Darby canine kidney (MDCK) cells has been widely used for high-throughput anti-influenza drug screening, but the fact that the MDCK cells are not human cells constitutes a disadvantage when searching for new therapeutic agents for human use. We have developed a highly sensitive cell-based imaging assay for the identification of inhibitors of influenza A and B virus that is high-throughput compatible using the A549 human cell line. The assay has also been optimized for the assessment of the neutralizing effect of anti-influenza antibodies in the absence of trypsin, which allows testing of purified antibodies and serum samples. This assay platform can be applied to full high-throughput screening campaigns or later stages requiring quantitative potency determinations for structure-activity relationships.
Collapse
Affiliation(s)
- Yohanka Martinez-Gzegozewska
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States.
| | - Lynn Rasmussen
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Sara McKellip
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Anna Manuvakhova
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - N Miranda Nebane
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Andrew J Reece
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Pedro Ruiz
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Melinda Sosa
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Robert Bostwick
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| | - Paige Vinson
- Scientific Platforms Division, Southern Research, High-Throughput Screening Center, Birmingham, Alabama, United States
| |
Collapse
|
3
|
Roth JR, Rush T, Thompson SJ, Aldaher AR, Dunn TB, Mesina JS, Cochran JN, Boyle NR, Dean HB, Yang Z, Pathak V, Ruiz P, Wu M, Day JJ, Bostwick JR, Suto MJ, Augelli-Szafran CE, Roberson ED. Development of small-molecule Tau-SH3 interaction inhibitors that prevent amyloid-β toxicity and network hyperexcitability. Neurotherapeutics 2024; 21:e00291. [PMID: 38241154 PMCID: PMC10903085 DOI: 10.1016/j.neurot.2023.10.001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/24/2023] [Accepted: 10/24/2023] [Indexed: 01/21/2024] Open
Abstract
Alzheimer's disease (AD) is the leading cause of dementia and lacks highly effective treatments. Tau-based therapies hold promise. Tau reduction prevents amyloid-β-induced dysfunction in preclinical models of AD and also prevents amyloid-β-independent dysfunction in diverse disease models, especially those with network hyperexcitability, suggesting that strategies exploiting the mechanisms underlying Tau reduction may extend beyond AD. Tau binds several SH3 domain-containing proteins implicated in AD via its central proline-rich domain. We previously used a peptide inhibitor to demonstrate that blocking Tau interactions with SH3 domain-containing proteins ameliorates amyloid-β-induced dysfunction. Here, we identify a top hit from high-throughput screening for small molecules that inhibit Tau-FynSH3 interactions and describe its optimization with medicinal chemistry. The resulting lead compound is a potent cell-permeable Tau-SH3 interaction inhibitor that binds Tau and prevents amyloid-β-induced dysfunction, including network hyperexcitability. These data support the potential of using small molecule Tau-SH3 interaction inhibitors as a novel therapeutic approach to AD.
Collapse
Affiliation(s)
- Jonathan R Roth
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Travis Rush
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Samantha J Thompson
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Adam R Aldaher
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Trae B Dunn
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Jacob S Mesina
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - J Nicholas Cochran
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Nicholas R Boyle
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Hunter B Dean
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Zhengrong Yang
- Biochemistry and Molecular Genetics, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Vibha Pathak
- Chemistry Department, Southern Research, Birmingham, AL, USA
| | - Pedro Ruiz
- Chemistry Department, Southern Research, Birmingham, AL, USA
| | - Mousheng Wu
- Chemistry Department, Southern Research, Birmingham, AL, USA
| | - Jeremy J Day
- Department of Neurobiology, University of Alabama at Birmingham, Birmingham, AL, USA
| | | | - Mark J Suto
- Chemistry Department, Southern Research, Birmingham, AL, USA
| | | | - Erik D Roberson
- Center for Neurodegeneration and Experimental Therapeutics, Alzheimer's Disease Center, Department of Neurology, University of Alabama at Birmingham, Birmingham, AL, USA.
| |
Collapse
|
4
|
Segura ÀG, Prohens L, Gassó P, Rodríguez N, Garcia-Rizo C, Moreno-Izco L, Andreu-Bernabeu Á, Zorrilla I, Mane A, Rodriguez-Jimenez R, Roldán A, Sarró S, Ibáñez Á, Usall J, Sáiz PA, Cuesta MJ, Parellada M, González-Pinto A, Berrocoso E, Bernardo M, Mas S, Mezquida G, Arbelo N, De Matteis M, Galvañ J, Duque Guerra A, Arias I Queralt L, Perez-Bacigalupe M, Gonzalez-Ortega I, Toll A, Casanovas F, Sanchez-Pastor L, Valtueña M, Pomarol-Clotet E, García-León MÁ, Butjosa A, Rubio-Abadal E, Ribeiro M, López-Ilundain JM, Saiz-Ruiz J, León-Quismondo L, Rivero O, Ruiz P, Echevarría RS, García-Portilla MP. The polygenic basis of relapse after a first episode of schizophrenia. Eur Neuropsychopharmacol 2023; 75:80-92. [PMID: 37603902 DOI: 10.1016/j.euroneuro.2023.06.003] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 02/15/2023] [Revised: 05/31/2023] [Accepted: 06/07/2023] [Indexed: 08/23/2023]
Abstract
Little is known about genetic predisposition to relapse. Previous studies have linked cognitive and psychopathological (mainly schizophrenia and bipolar disorder) polygenic risk scores (PRS) with clinical manifestations of the disease. This study aims to explore the potential role of PRS from major mental disorders and cognition on schizophrenia relapse. 114 patients recruited in the 2EPs Project were included (56 patients who had not experienced relapse after 3 years of enrollment and 58 patients who relapsed during the 3-year follow-up). PRS for schizophrenia (PRS-SZ), bipolar disorder (PRS-BD), education attainment (PRS-EA) and cognitive performance (PRS-CP) were used to assess the genetic risk of schizophrenia relapse.Patients with higher PRS-EA, showed both a lower risk (OR=0.29, 95% CI [0.11-0.73]) and a later onset of relapse (30.96± 1.74 vs. 23.12± 1.14 months, p=0.007. Our study provides evidence that the genetic burden of neurocognitive function is a potentially predictors of relapse that could be incorporated into future risk prediction models. Moreover, appropriate treatments for cognitive symptoms appear to be important for improving the long-term clinical outcome of relapse.
Collapse
Affiliation(s)
- Àlex-González Segura
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
| | - Llucia Prohens
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain
| | - Patricia Gassó
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain
| | - Natalia Rodríguez
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain
| | - Clemente Garcia-Rizo
- Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Hospital Clínic de Barcelona, Neuroscience Institute, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Lucía Moreno-Izco
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Álvaro Andreu-Bernabeu
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| | - Iñaki Zorrilla
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, BIOARABA Health Research Institute Vitoria, Hospital Universitario de Alava, Spain; University of the Basque Country, Vitoria, Spain
| | - Anna Mane
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Hospital del Mar, Medical Research Institute (IMIM), Barcelona, Spain
| | - Roberto Rodriguez-Jimenez
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Universidad Complutense de Madrid (UCM), Madrid, Spain; Department of Psychiatry. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Alexandra Roldán
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Salvador Sarró
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain
| | - Ángela Ibáñez
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Alcalá de Henares, Universidad de Alcalá, Spain
| | - Judith Usall
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
| | - Pilar A Sáiz
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, University of Oviedo, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA). Instituto de Neurociencias del Principado de Asturias (INEUROPA). Mental Health Services of the Principality of Asturias (SESPA), Oviedo, Spain
| | - Manuel J Cuesta
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Mara Parellada
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| | - Ana González-Pinto
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, BIOARABA Health Research Institute Vitoria, Hospital Universitario de Alava, Spain; University of the Basque Country, Vitoria, Spain
| | - Ester Berrocoso
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Neuropsychopharmacology and Psychobiology Research Group, Department of Psychology, University of Cádiz, Cádiz, Spain; Instituto de Investigación e Innovación Biomédica de Cádiz, INiBICA, Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - Miquel Bernardo
- Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Hospital Clínic de Barcelona, Neuroscience Institute, Barcelona, Spain; Department of Medicine, University of Barcelona, Barcelona, Spain
| | - Sergi Mas
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain.
| | - Gisela Mezquida
- Department of Clinical Foundations, Pharmacology Unit, University of Barcelona, Barcelona, Spain; Institut d'investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Barcelona Clínic Schizophrenia Unit (BCSU), Hospital Clínic de Barcelona, Neuroscience Institute, Barcelona, Spain
| | - Néstor Arbelo
- Barcelona Clínic Schizophrenia Unit (BCSU), Hospital Clínic de Barcelona, Neuroscience Institute, Barcelona, Spain
| | - Mario De Matteis
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| | - Joaquín Galvañ
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Child and Adolescent Psychiatry, Institute of Psychiatry and Mental Health, Hospital General Universitario Gregorio Marañón, IiSGM, Madrid, Spain; School of Medicine, Universidad Complutense, Madrid, Spain
| | - Alejandra Duque Guerra
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Laia Arias I Queralt
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Institut d'Investigació Biomèdica-Sant Pau (IIB-SANT PAU), Hospital de la Santa Creu i Sant Pau, Barcelona, Spain; Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | - Maria Perez-Bacigalupe
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, BIOARABA Health Research Institute Vitoria, Hospital Universitario de Alava, Spain; University of the Basque Country, Vitoria, Spain
| | - Itxaso Gonzalez-Ortega
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, BIOARABA Health Research Institute Vitoria, Hospital Universitario de Alava, Spain; University of the Basque Country, Vitoria, Spain
| | - Alba Toll
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Hospital del Mar, Medical Research Institute (IMIM), Barcelona, Spain
| | | | - Luis Sanchez-Pastor
- Department of Psychiatry. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Mercedes Valtueña
- Department of Psychiatry. Instituto de Investigación Sanitaria Hospital 12 de Octubre (imas12), Madrid, Spain
| | - Edith Pomarol-Clotet
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain
| | - Maria Ángeles García-León
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; FIDMAG Germanes Hospitalàries Research Foundation, Barcelona, Spain
| | - Ana Butjosa
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
| | - Elena Rubio-Abadal
- Institut de Recerca Sant Joan de Déu, Esplugues de Llobregat, Spain; Parc Sanitari Sant Joan de Déu, Sant Boi de Llobregat, Spain
| | - María Ribeiro
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Jose M López-Ilundain
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, Hospital Universitario de Navarra, Pamplona, Spain; Navarra Institute for Health Research (IdiSNA), Pamplona, Spain
| | - Jeronimo Saiz-Ruiz
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Alcalá de Henares, Universidad de Alcalá, Spain
| | - Luis León-Quismondo
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Hospital Universitario Ramón y Cajal, IRYCIS, Madrid, Spain; Alcalá de Henares, Universidad de Alcalá, Spain
| | - Olga Rivero
- Biomedical Research Institute INCLIVA, Fundación Investigación Hospital Clínico de Valencia, Valencia, Spain; Departament of Genetics, Universitat de València, Valencia, Spain
| | - Pedro Ruiz
- Hospital Clínico Universitario and Instituto de Investigación Sanitaria (IIS) Aragón, Zaragoza, Spain; Department of Medicine and Psychiatry.Universidad de Zaragoza, Zaragoza, Spain
| | - Rafael Segarra Echevarría
- Cruces University Hospital, BioCruces Health Research Institute, Vizcaya, Spain; University of the Basque Country (UPV/EHU) Vizcaya, Spain
| | - M Paz García-Portilla
- Centro de Investigación Biomédica en red en salud Mental (CIBERSAM), Spain; Department of Psychiatry, University of Oviedo, Oviedo, Spain; Instituto de Investigación Sanitaria del Principado de Asturias (ISPA). Instituto de Neurociencias del Principado de Asturias (INEUROPA). Mental Health Services of the Principality of Asturias (SESPA), Oviedo, Spain
| |
Collapse
|
5
|
Kannon M, Nebane NM, Ruiz P, McKellip S, Vinson PN, Mitra A. A Novel Approach To Identify Inhibitors of Iron Acquisition Systems of Pseudomonas aeruginosa. Microbiol Spectr 2022; 10:e0243722. [PMID: 36098531 PMCID: PMC9604216 DOI: 10.1128/spectrum.02437-22] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 06/28/2022] [Accepted: 08/26/2022] [Indexed: 01/04/2023] Open
Abstract
Pseudomonas aeruginosa is an opportunistic pathogen that has been declared by the World Health Organization as a "priority 1 critical pathogen" needing immediate new strategies for chemotherapy. During infection, P. aeruginosa uses redundant mechanisms to acquire ferric, heme (Hm), or ferrous iron from the host to survive and colonize. Significant efforts have been undertaken to develop siderophore blockers to inhibit ferric iron acquisition by P. aeruginosa, but there is a lack of inhibitors that can block Hm or ferrous iron acquisition by P. aeruginosa. We developed and employed a targeted high-throughput screen (HTS) and identified a molecule(s) that can specifically inhibit the Hm and ferrous iron acquisition systems of P. aeruginosa. Our targeted approach relies on screening a small-molecule library against P. aeruginosa under three growth conditions, where the only variable was the iron source (ferric, Hm, or ferrous iron). Each condition served as a counterscreen for the other, and we identified molecules that inhibit the growth of P. aeruginosa in the presence of only Hm or ferrous iron. Our data indicate that econazole, bithionate, and raloxifene inhibit the growth of P. aeruginosa in the presence of Hm and that oxyquinoline inhibits the growth of P. aeruginosa in the presence of ferrous iron. These iron-specific inhibitors do not interfere with the activity of meropenem, a commercial antipseudomonal, and can also increase meropenem activity. In conclusion, we present a proof of concept of a successful targeted conditional screening method by which we can identify specific iron acquisition inhibitors. This approach is highly adaptable and can easily be extended to any other pathogen. IMPORTANCE Since acquiring iron is paramount to P. aeruginosa's survival and colonization in the human host, developing novel strategies to block the access of P. aeruginosa to host iron will allow us to starve it of an essential nutrient. P. aeruginosa uses siderophore, heme, or ferrous iron uptake systems to acquire iron in the human host. We have developed a novel approach through which we can directly identify molecules that can prevent P. aeruginosa from utilizing heme or ferrous iron. This approach overcomes the need for the in silico design of molecules and identifies structurally diverse biologically active inhibitor molecules. This screening approach is adaptable and can be extended to any pathogen. Since Gram-negative pathogens share many similarities in iron acquisition at both the mechanistic and molecular levels, our screening approach presents a significant opportunity to develop novel broad-spectrum iron acquisition inhibitors of Gram-negative pathogens.
Collapse
Affiliation(s)
- Mamie Kannon
- Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA
| | - N. Miranda Nebane
- High Throughput Screening Center, Southern Research, Birmingham, Alabama, USA
| | - Pedro Ruiz
- High Throughput Screening Center, Southern Research, Birmingham, Alabama, USA
| | - Sara McKellip
- High Throughput Screening Center, Southern Research, Birmingham, Alabama, USA
| | - Paige N. Vinson
- High Throughput Screening Center, Southern Research, Birmingham, Alabama, USA
| | - Avishek Mitra
- Department of Microbiology and Molecular Genetics, Oklahoma State University, Stillwater, Oklahoma, USA
| |
Collapse
|
6
|
Ciscar A, Ruiz P, Saez E, Vila M, Gomez M, Troyano D, Abadal M, Pereira JA, Badia JM. OC-069 EFECTIVENESS OF PROPHYLACTIC ONLAY MESH FOR PREVENTION OF TROCAR HERNIA: PRELIMINARY RESULTS OF A RANDOMIZED CLINICAL TRIAL. Br J Surg 2022. [DOI: 10.1093/bjs/znac308.081] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
Abstract
Aim
Trocar site hernia (TSH) incidence is a common complication of laparoscopic surgery. In the literature there is a lack of tools to prevent it. Our aim was to assess the effectiveness and safety of a prophylactic measure to decrease it.
Methods
A multicentric randomized clinical trial was performed in high-risk patients (diabetes mellitus and/or age ≥70 years and/or BMI ≥30 Kg/m2 and/or extended incision for specimen retrieval) who underwent laparoscopic cholecystectomy in an elective or emergency setting. Patients were allocated to prophylactic onlay polypropylene mesh fixation (intervention) or standard trocar closure (control). The main aim was to analyze the efficacy of the intervention, being TSH incidence the primary outcome. Clinical and radiological follow up was atleast 1 year after surgery. Secondary endpoints were technique-related complications.
Results
134 patients were included (70 and 62 to intervention and control arm, respectively). Groups were homogeneous. Mean [SD] age, 64.8 (17.3) years; 80 (60, 6%) women. The cumulative TSH incidence was lower in the intervention group although not reaching significant differences, either when were radiologically (16 [26.7%] vs 17 [37%], p = 0.294) or clinically assessed (9 [17.6%] vs 9 [24.3], p = 0.593). No differences in surgical site infection, hematoma or seroma were detected. Mean follow-up was 736 days (min. 365 – max. 1294).
Conclusions
Our preliminary results points out that the overall TSH incidence is extremely high when properly assessed. A polypropylene onlay mesh would not be an effective measure to decrease the TSH incidence. Radiological evaluation would show more accuracy.
Collapse
Affiliation(s)
- A Ciscar
- General Surgery, Hospital de Mataró - Consorci Sanitari del Maresme , Mataró , Spain
| | - P Ruiz
- General Surgery, Hospital de Granollers , Granollers , Spain
| | - E Saez
- General Surgery, Hospital de Sant Boi , Sant Boi de Llobregat , Spain
| | - M Vila
- General Surgery, Hospital de Mataró - Consorci Sanitari del Maresme , Mataró , Spain
| | - M Gomez
- General Surgery, Hospital de Calella , Calella , Spain
| | - D Troyano
- General Surgery, Hospital Esperit Sant , Santa Coloma de Gramenet , Spain
| | - M Abadal
- General Surgery, Hospital de Mataró - Consorci Sanitari del Maresme , Mataró , Spain
| | - J A Pereira
- General Surgery, Hospital Universitari del Mar , Barcelona , Spain
| | - J M Badia
- General Surgery, Hospital de Granollers , Granollers , Spain
| |
Collapse
|
7
|
Teseo S, Otani S, Brinch C, Leroy S, Ruiz P, Desvaux M, Forano E, Aarestrup FM, Sapountzis P. A global phylogenomic and metabolic reconstruction of the large intestine bacterial community of domesticated cattle. Microbiome 2022; 10:155. [PMID: 36155629 PMCID: PMC9511753 DOI: 10.1186/s40168-022-01357-1] [Citation(s) in RCA: 5] [Impact Index Per Article: 2.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 03/21/2022] [Accepted: 08/24/2022] [Indexed: 05/30/2023]
Abstract
BACKGROUND The large intestine is a colonization site of beneficial microbes complementing the nutrition of cattle but also of zoonotic and animal pathogens. Here, we present the first global gene catalog of cattle fecal microbiomes, a proxy of the large intestine microbiomes, from 436 metagenomes from six countries. RESULTS Phylogenomics suggested that the reconstructed genomes and their close relatives form distinct branches and produced clustering patterns that were reminiscent of the metagenomics sample origin. Bacterial taxa had distinct metabolic profiles, and complete metabolic pathways were mainly linked to carbohydrates and amino acids metabolism. Dietary changes affected the community composition, diversity, and potential virulence. However, predicted enzymes, which were part of complete metabolic pathways, remained present, albeit encoded by different microbes. CONCLUSIONS Our findings provide a global insight into the phylogenetic relationships and the metabolic potential of a rich yet understudied bacterial community and suggest that it provides valuable services to the host. However, we tentatively infer that members of that community are not irreplaceable, because similar to previous findings, symbionts of complex bacterial communities of mammals are expendable if there are substitutes that can perform the same task. Video Abstract.
Collapse
Affiliation(s)
- S Teseo
- School of Biological Sciences, Nanyang Technological University, Singapore, Singapore
| | - S Otani
- National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark
| | - C Brinch
- National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark
| | - S Leroy
- Université Clermont Auvergne, INRAE, UMR 0454 MEDIS, Clermont-Ferrand, France
| | - P Ruiz
- Université Clermont Auvergne, INRAE, UMR 0454 MEDIS, Clermont-Ferrand, France
| | - M Desvaux
- Université Clermont Auvergne, INRAE, UMR 0454 MEDIS, Clermont-Ferrand, France
| | - E Forano
- Université Clermont Auvergne, INRAE, UMR 0454 MEDIS, Clermont-Ferrand, France
| | - F M Aarestrup
- National Food Institute, Technical University of Denmark, Kongens Lyngby, Denmark
| | - P Sapountzis
- Université Clermont Auvergne, INRAE, UMR 0454 MEDIS, Clermont-Ferrand, France.
| |
Collapse
|
8
|
Ruiz P, Boone S. LP-34 Race/ethnicity and age-based susceptibilities in environmental exposures to PFAS: A literature review of exposures associated with altered serum lipids. Toxicol Lett 2022. [DOI: 10.1016/j.toxlet.2022.07.774] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/14/2022]
|
9
|
Herraiz S, Ruiz P, Garrido N, Ballester A, Vergara V, Cruz M, Requena A, García-Velasco JA, Muñoz M. P-796 Intraovarian injection of plasma rich in growth factors improves ovarian reserve and reproductive outcomes in women with diminished ovarian reserve. Hum Reprod 2022. [DOI: 10.1093/humrep/deac104.058] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/14/2022] Open
Abstract
Abstract
Study question
Does Plasma rich in growth factors (PRGF) ovarian injection increase the ovarian reserve biomarkers in women with diminished ovarian reserve?
Summary answer
PRGF injection increased Antimüllerian hormone (AMH) levels and antral follicular count (AFC) since the first follow-up after treatment allowing the initiation of ovarian stimulation cycles.
What is known already
Several techniques based on in vitro activation, ovarian fragmentation and stem cell ovarian transplantation have been proposed to reactivate ovarian function and increase IVF success in women with premature ovarian insufficiency and poor ovarian response. However, less invasive and feasible approaches are still required for those patients where egg donation is the only practical option.
Platelet rich plasma (PRP) and PRGF contain a high concentration of platelets, which carry more than 800 types of proteins, cytokines, hormones, and chemoattractants. Indeed, intraovarian PRP injection has recently been used in different case series and cohort studies of POI women with encouraging results.
Study design, size, duration
Retrospective study with 104 women aging 23-45 years who received a PRGF intraovarian injection (REGENERA-Ovario) was conducted between 2020 and 2021 at IVIRMA Alicante (Spain). Study was approved by the IRB committee of La Fe University Hospital (2112-FIVI-109-SH).
Participants/materials, setting, methods
Patients underwent a PRGF injection (Endoret kit; B.T.I. Biotechnology Institute S.L, Spain) in both ovaries and a follow up of ovarian reserve biomarkers (AFC, AMH) and follicle stimulating hormone (FSH) to evaluate follicular reactivation seeking IVF or spontaneous pregnancy. The follow up visits ranged from 1 to 5 months and were developed on a monthly basis after treatment or after menses recovery in POI. Study variables were compared to basal levels with a paired t-test.
Main results and the role of chance
Overall, 104 women (age: 38.7±2.0 years; BMI: 22.1±2.9) with diminished ovarian reserves underwent a PRGF intraovarian injection (3.3±0.8ml PRGF/each ovary). Prior to treatment, our cohort was characterized high serum FSH (21.8±4.1mIU/mL), low AMH levels (0.25±0.37ng/ml), and an ovarian volume of 6.3±2.3cm3.
Eighty-eight of them fulfilled the 1st follow up visit and showed an increase of serum AMH (0.25±0.37ng/ml vs. 0.32±0.36ng/ml, p = 0.008), and AFC in both ovaries (2.1±1.9 vs. 3.2±2.4, p < 0.0001) compared to basal levels, achieving ovarian reactivation in 55.9% of them and IVF cycle initiation in 19.3%. These improvements were higher 2 months after treatment (55 patients), with increased antral follicles (AFC-2: 2.9±2.5, p = 0.0001) and ovarian activation in 58.2%, and IVF start in 43.9% of patients. Similar results were observed during the 3rd follow up accomplished by 30 women and lasted until the 5th visit (n = 8), although the reduced patient number at this point.
A total of 44 IVF cycles were started and oocyte pick-up was successfully developed in 72.7% of them with a mean number of 3.3±4.2MII oocytes, 1.8±2.1 fertilized oocytes and 1.5±2.0 embryos per cycle. Indeed, 6 pregnancies were obtained during this period, 2 of them after embryo transfer and 4 by natural conception.
Limitations, reasons for caution
Our results are encouraging but a large cohort of patients with a longer follow up period is needed to establish the efficacy and duration of the PRGF positive ovarian effects. Moreover, a proper comparison with a control group with the same characteristics and no PRGF intervention is still required.
Wider implications of the findings
PRGF intraovarian injection reactivates follicle growth and allows IVF cycle initiation and embryo generation in a poor prognosis population of patients with diminished ovarian reserve. The effects persisted for several months after treatment.
Trial registration number
2112-FIVI-109-SH
Collapse
Affiliation(s)
- S Herraiz
- Fundación IVI-IIS La Fe, Innovation , Valencia, Spain
| | - P Ruiz
- IVIRMA Alicante, Reproductive Medicine Unit , Alicante, Spain
| | - N Garrido
- Fundación IVI-IIS La Fe, Innovation , Valencia, Spain
| | - A Ballester
- IVIRMA Alicante, Reproductive Medicine Unit , Alicante, Spain
| | - V Vergara
- IVIRMA Madrid, Reproductive Medicine Unit , Madrid, Spain
| | - M Cruz
- IVIRMA Madrid, Medical Affairs , Madrid, Spain
| | - A Requena
- IVIRMA Madrid, Medical Affairs , Madrid, Spain
| | | | - M Muñoz
- IVIRMA Alicante, Reproductive Medicine Unit , Alicante, Spain
| |
Collapse
|
10
|
Yatchang MF, Mathew B, Srivastava RK, Khan J, Muzaffar S, Zhang S, Wu M, Zhai L, Ruiz P, Agarwal A, Bostwick JR, Suto MJ, Athar M, Augelli-Szafran CE. Development of BRD4 inhibitors as anti-inflammatory agents and antidotes for arsenicals. Bioorg Med Chem Lett 2022; 64:128696. [PMID: 35318165 PMCID: PMC9017782 DOI: 10.1016/j.bmcl.2022.128696] [Citation(s) in RCA: 3] [Impact Index Per Article: 1.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 02/18/2022] [Revised: 03/16/2022] [Accepted: 03/17/2022] [Indexed: 11/26/2022]
Abstract
Arsenicals belong to the class of chemical warfare agents known as vesicants, which are highly reactive, toxic and cause robust inflammatory response. Cutaneous exposure to arsenicals causes a wide range of systemic organ damage, beginning with cutaneous injuries, and later manifest multi-organ damage and death. Thus, the development of suitable antidotes that can effectively block injury following exposure to these agents is of great importance. Bromodomain 4 (BRD4), a member of the bromodomain and extra terminal domain (BET) family, plays crucial role in regulating transcription of inflammatory, proliferation and cell cycle genes. In this context, the development of potent small molecule inhibitors of BRD4 could serve as potential antidotes for arsenicals. Herein, we describe the synthesis and biological evaluation of a series of compounds.
Collapse
Affiliation(s)
- Marina Fosso Yatchang
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Bini Mathew
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Ritesh K Srivastava
- UAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Jasim Khan
- UAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Suhail Muzaffar
- UAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - Sixue Zhang
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Mousheng Wu
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Ling Zhai
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Pedro Ruiz
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Anupam Agarwal
- UAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA; Department of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA
| | - James R Bostwick
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Mark J Suto
- Scientific Platforms, Southern Research, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Mohammad Athar
- UAB Research Center of Excellence in Arsenicals, School of Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
| | | |
Collapse
|
11
|
Mortier P, Vilagut G, Alayo I, Ferrer M, Amigo F, Aragonès E, Aragón-Peña A, Asúnsolo del Barco A, Campos M, Espuga M, González-Pinto A, Haro J, López Fresneña N, Martínez de Salázar A, Molina J, Ortí-Lucas R, Parellada M, Pelayo-Terán J, Pérez-Gómez B, Pérez-Zapata A, Pijoan J, Plana N, Polentinos-Castro E, Portillo-Van Diest A, Puig M, Rius C, Sanz F, Serra C, Urreta-Barallobre I, Kessler R, Bruffaerts R, Vieta E, Pérez-Solá V, Alonso J, Alayo I, Alonso M, Álvarez M, Amann B, Amigo FF, Anmella G, Aragón A, Aragonés N, Aragonès E, Arizón AI, Asunsolo A, Ayora A, Ballester L, Barbas P, Basora J, Bereciartua E, Ignasi Bolibar IB, Bonfill X, Cotillas A, Cuartero A, de Paz C, Cura ID, Jesus del Yerro M, Diaz D, Domingo JL, Emparanza JI, Espallargues M, Espuga M, Estevan P, Fernandez MI, Fernandez T, Ferrer M, Ferreres Y, Fico G, Forjaz MJ, Barranco RG, Garcia TorrecillasC. Garcia-Ribera JM, Garrido A, Gil E, Gomez M, Gomez J, Pinto AG, Haro JM, Hernando M, Insigna MG, Iriberri M, Jimenez N, Jimenez X, Larrauri A, Leon F, Lopez-Fresneña N, Lopez C, Lopez-Atanes Juan Antonio Lopez-Rodriguez M, Lopez-Cortacans G, Marcos A, Martin J, Martin V, Martinez-Cortés M, Martinez-Martinez R, Martinez de Salazar AD, Martinez I, Marzola M, Mata N, Molina JM, de Dios Molina J, Molinero E, Mortier P, Muñoz C, Murru A, Olmedo J, Ortí RM, Padrós R, Pallejà M, Parra R, Pascual J, Pelayo JM, Pla R, Plana N, Aznar CP, Gomez BP, Zapata AP, Pijoan JI, Polentinos E, Puertolas B, Puig MT, Quílez A, Quintana MJ, Quiroga A, Rentero D, Rey C, Rius C, Rodriguez-Blazquez C, Rojas MJ, Romero Y, Rubio G, Rumayor M, Ruiz P, Saenz M, Sanchez J, Sanchez-Arcilla I, Sanz F, Serra C, Serra-Sutton V, Serrano M, Sola S, Solera S, Soto M, Tarrago A, Tolosa N, Vazquez M, Viciola M, Vieta E, Vilagut G, Yago S, Yañez J, Zapico Y, Zorita LM, Zorrilla I, Zurbano SL, Perez-Solá V. Four-month incidence of suicidal thoughts and behaviors among healthcare workers after the first wave of the Spain COVID-19 pandemic. J Psychiatr Res 2022; 149:10-17. [PMID: 35217315 PMCID: PMC8852847 DOI: 10.1016/j.jpsychires.2022.02.009] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 11/13/2021] [Revised: 02/08/2022] [Accepted: 02/14/2022] [Indexed: 12/22/2022]
Abstract
Healthcare workers (HCW) are at high risk for suicide, yet little is known about the onset of suicidal thoughts and behaviors (STB) in this important segment of the population in conjunction with the COVID-19 pandemic. We conducted a multicenter, prospective cohort study of Spanish HCW active during the COVID-9 pandemic. A total of n = 4809 HCW participated at baseline (May-September 2020; i.e., just after the first wave of the pandemic) and at a four-month follow-up assessment (October-December 2020) using web-based surveys. Logistic regression assessed the individual- and population-level associations of separate proximal (pandemic) risk factors with four-month STB incidence (i.e., 30-day STB among HCW negative for 30-day STB at baseline), each time adjusting for distal (pre-pandemic) factors. STB incidence was estimated at 4.2% (SE = 0.5; n = 1 suicide attempt). Adjusted for distal factors, proximal risk factors most strongly associated with STB incidence were various sources of interpersonal stress (scaled 0-4; odds ratio [OR] range = 1.23-1.57) followed by personal health-related stress and stress related to the health of loved ones (scaled 0-4; OR range 1.30-1.32), and the perceived lack of healthcare center preparedness (scaled 0-4; OR = 1.34). Population-attributable risk proportions for these proximal risk factors were in the range 45.3-57.6%. Other significant risk factors were financial stressors (OR range 1.26-1.81), isolation/quarantine due to COVID-19 (OR = 1.53) and having changed to a specific COVID-19 related work location (OR = 1.72). Among other interventions, our findings call for healthcare systems to implement adequate conflict communication and resolution strategies and to improve family-work balance embedded in organizational justice strategies.
Collapse
Affiliation(s)
- P. Mortier
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Corresponding author. IMIM, PRBB Building. Carrer del Doctor Aiguader 88, 08003, Barcelona, Spain
| | - G. Vilagut
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - I. Alayo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - M. Ferrer
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| | - F. Amigo
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - E. Aragonès
- Institut d’Investigació en Atenció Primària IDIAP Jordi Gol, Barcelona, Spain,Atenció Primària Camp de Tarragona, Institut Català de la Salut, Spain
| | - A. Aragón-Peña
- Epidemiology Unit, Regional Ministry of Health, Community of Madrid, Madrid, Spain,Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain
| | - A. Asúnsolo del Barco
- Department of Surgery, Medical and Social Sciences, Faculty of Medicine and Health Sciences, University of Alcala, Alcalá de Henares, Spain,Ramón y Cajal Institute of Sanitary Research (IRYCIS), Madrid, Spain,Department of Epidemiology and Biostatistics, Graduate School of Public Health and Health Policy, The City University of New York, New York, NY, United States
| | - M. Campos
- Service of Prevention of Labor Risks, Medical Emergencies System, Generalitat de Catalunya, Spain
| | - M. Espuga
- Occupational Health Service. Hospital Universitari Vall d’Hebron, Barcelona, Spain
| | - A. González-Pinto
- Hospital Universitario Araba-Santiago, Vitoria-Gasteiz, Spain,CIBER Salud Mental (CIBERSAM), Madrid, Spain
| | - J.M. Haro
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Parc Sanitari Sant Joan de Déu, Barcelona, Spain,Universitat Autònoma de Barcelona (UAB), Barcelona, Spain
| | | | | | - J.D. Molina
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Villaverde Mental Health Center. Clinical Management Area of Psychiatry and Mental Health, Psychiatric Service, Hospital Universitario 12 de Octubre, Madrid, Spain,Research Institute Hospital 12 de Octubre (i+12), Madrid, Spain,Faculty of Health Sciences, Universidad Francisco de Vitoria, Madrid, Spain
| | | | - M. Parellada
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - J.M. Pelayo-Terán
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Servicio de Psiquiatría y Salud Mental. Hospital el Bierzo, Gerencia de Asistencia Sanitaria del Bierzo (GASBI), Gerencia Regional de Salud de Castilla y Leon (SACYL), Ponferrada, León, Spain,Area de Medicina Preventiva y Salud Pública. Universidad de León, León, Spain
| | - B. Pérez-Gómez
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,National Center of Epidemiology, Instituto de Salud Carlos III (ISCIII), Madrid, Spain
| | - A. Pérez-Zapata
- Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain
| | - J.I. Pijoan
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Hospital Universitario Cruces/ OSI EEC, Bilbao, Spain, Biocruces-Bizkaia Health Research Institute
| | - N. Plana
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Príncipe de Asturias University Hospital, Alcalá de Henares, Madrid, Spain
| | - E. Polentinos-Castro
- Fundación Investigación e Innovación Biosanitaria de AP, Comunidad de Madrid, Madrid, Spain,Research Unit. Primary Care Management. Madrid Health Service, Madrid, Spain,Department of Medical Specialities and Public Health. King Juan Carlos University, Madrid, Spain,Health Services Research Network on Chronic Diseases (REDISSEC), Madrid, Spain
| | - A. Portillo-Van Diest
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain
| | - M.T. Puig
- Universitat Autònoma de Barcelona (UAB), Barcelona, Spain,Department of Epidemiology and Public Health, Hospital de la Santa Creu i Sant Pau, Barcelona, Spain,Biomedical Research Institute Sant Pau (IIB Sant Pau), Barcelona, Spain,CIBER Enfermedades Cardiovasculares (CIBERCV), Madrid, Spain
| | - C. Rius
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Agència de Salut Pública de Barcelona, Barcelona, Spain
| | - F. Sanz
- Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain,Research Progamme on Biomedical Informatics (GRIB), Hospital del Mar Medical Research Institute (IMIM), Barcelona, Spain,Instituto Nacional de Bioinformatica - ELIXIR-ES, Barcelona, Spain
| | - C. Serra
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Parc de Salut Mar PSMAR, Barcelona, Spain,CiSAL-Centro de Investigación en Salud Laboral, IMIM/UPF, Barcelona, Spain
| | - I. Urreta-Barallobre
- CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Osakidetza Basque Health Service, Donostialdea Integrated Health Organisation, Donostia University Hospital, Clinical Epidemiology Unit, San Sebastián, Spain,Biodonostia Health Research Institute, Clinical Epidemiology, San Sebastián, Spain
| | - R.C. Kessler
- Department of Health Care Policy, Harvard Medical School, Boston, MA, USA
| | - R. Bruffaerts
- Center for Public Health Psychiatry, Universitair Psychiatrisch Centrum, KU Leuven, Leuven, Belgium
| | - E. Vieta
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Institute of Neuroscience, Hospital Clinic, University of Barcelona, IDIBAPS, Barcelona, Spain
| | - V. Pérez-Solá
- CIBER Salud Mental (CIBERSAM), Madrid, Spain,Universitat Autònoma de Barcelona (UAB), Barcelona, Spain,Parc de Salut Mar PSMAR, Barcelona, Spain
| | - J. Alonso
- Health Services Research Unit, IMIM-Institut Hospital del Mar d’Investigacions Mèdiques, Barcelona, Spain,CIBER Epidemiología y Salud Pública (CIBERESP), Spain,Department of Experimental and Health Sciences, Pompeu Fabra University, Barcelona, Spain
| | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
12
|
Roth JR, Rush T, Pugh DA, Dean HB, Cochran JN, Thompson SJ, Aldaher AR, Mesina JS, Ruiz P, Pathak V, Wu M, Bostwick JR, Suto MJ, Augelli‐Szafran CE, Roberson ED. Development of small‐molecule tau‐SH3 interaction inhibitors that prevent amyloid‐β toxicity. Alzheimers Dement 2021. [DOI: 10.1002/alz.055501] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022]
Affiliation(s)
| | - Travis Rush
- University of Alabama at Birmingham Birmingham AL USA
| | - Derian A Pugh
- University of Alabama at Birmingham Birmingham AL USA
| | - Hunter B Dean
- University of Alabama at Birmingham Birmingham AL USA
| | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
13
|
Ortiz A, Roger M, Jiménez VM, Perez JCR, Furlano M, Atxer LS, Zurro DG, Casabona CMR, Zurro DG, Gómez CG, Bermúdez PP, Armisen MA, López SA, Porras IG, Ruiz JG, Orgaz JMM, Barón MM, Ortiz PDS, Fuente GDADL, Gili BQ, Fresnedo GF, Cabrera SS, Contreras JP, Pelicano MB, Blanca AM, Portillo MR, Álvarez JES, Romeo MJS, Pérez MG, Diezhandino MG, Marrero DH, Campo CF, García EM, Carmona DGC, Ramírez AT, Bellvis LM, Haym MB, Gómez MB, Martínez JMC, Garrit JMC, Garrido RSJ, Delgado JB, Marimont MB, Muñoz MOV, Villares JMP, Velázquez ÁS, Bonet LA, Bravo MÁG, Mateos FJM, Amador MM, Blanca AM, Miñano JAP, Belmonte AA, Jover AS, Rituerto DC, Sánchez FP, Arenas MD, Hernández RM, Serrano BM, Arduan AO, Sanz AB, Ramos AM, Córdoba-David G, García-Jiménez J, Fontecha-Barriuso M, Guerrero-Mauvecin J, Lopez-Díaz AM, Sánchez-Niño MD, Valiño-Rivas L, Cuarental L, Ribagorda M, Pintor-Chocano A, Favero C, Alvarez-Llamas G, Catalina MC, Fernández-Fernández B, Pérez-Gómez MV, Montaner ERAD, Prado RF, Rivera JR, Verde AMR, Luis-Lima S, Sánchez-Rodríguez J, Sánchez SP, Ortega MR, Parra EG, Mateos SR, Ortiz PJC, Expósito LM, Tejera-Muñoz A, Marchant V, Tejedor-Santamaria L, Agilar MA, Diekmann F, Genis BB, Salinas FO, Bajo MJR, Maneus EB, Guillen MA, Juárez JR, Rodríguez ML, Vicente IR, Pelicano JMB, Porras LFQ, Aguiar PVA, Font MX, Andujar AM, Cucchiari D, Marrah EM, M J, Piñeiro GJ, Salgado CM, Morales Martín AI, López Hernández FJ, Balboa NE, Vicente MP, Calvo IF, González LR, Vicente LV, Martínez SMS, Casanova Paso AG, Garriel MP, López JJV, Palacios AMC, Saénz DS, García PG, Bonilla JLA, Fernández Rodríguez MA, Galán AD, Marcos EM, Pérez-Aradros JC, José RMS, Zelaya FM, Panadés ES, Molina ÁG, Salido JA, Balcells RT, Criach EA, Encarnación MD, Perich LG, Furlano M, Girol CC, Terroba YA, Oliveras MP, Vila LE, Cabañas NS, Molas CF, Torres IS, Pelaez SL, Serra CR, Torres CC, Fajardo JPT, Lahuerta JIH, Herranz VM, Portillo MR, Malo AM, Cabrera SS, Castañeda JRM, Ortiz MER, Moreno JMM, Bermúdez AIR, Olmo RS, Pavón FG, Peregrin CM, Tejero EA, Villalba IL, Muñoz AC, Mier MVPRD, Martos CMP, Baltanas RL, Haad CR, Bartolomé MF, Valdemoros RL, Serres FEB, Díaz MN, Mariño FJJ, Sole LC, Saborido MIT, Majoral JS, Martínez ML, Calabia ER, Millán JCRS, López-Hoyos M, Benito-Hernández A, Fresnedo GF, Segundo DS, Valero R, García EC, Ona JGD, Llavona EC, Rodríguez FS, Gutiérrez RL, Peña HG, Pérez MG, Marrero DH, López V, Sola E, Cabello M, Caballero A, León M, Ruiz P, Alonso J, Navarro-González J, Mora-Fernández MDC, Donate-Correa J, Martín-Nuñez E, Delgado NP, Gigarrán-Guldris S, Pérez JCR, Teruel JLG, Castelao AM, Revilla JMV, Martínez CM, Stanojevic MB, Boque EC, Rosell MNS, Lamo VMD, Tocados JMD, Carrasco AG, López MB, Enriquez MC, Bardaji AM, Masot ND, Gómez AP, Sanjuan AE, Ortega AO, Fuentes RW, Guindo MDCDG, Fuentes MDCR, Ravassa FO, Molina MC, Tortosa CLR, Garrido RGDM, Romeo MJS, Jacobs-Cachá C, Matamoros OB, Mateos FM, Meneghini MAE, Roig JS, Betsabé IT, Larrea CL, Álvarez BS, Corte MDCD, Rodrigues-Diez RR, Vázquez AL, Rodríguez SG, Castiñeira JRV, Martín CM, Álvarez MLS, Iglesias VC, Borra JM, Rubio MAB, Gilsanz GDP, Cabrera ML, Heffernan JAJ, González MO, González OC, García MEG, Martín CJ, Correa PS, Ramos SA, Oliva ML, Becerra BR, Cabrera CV, Mateo GTG, Villanueva RS, García LÁ, Cannata Andía JB, Díaz MN, Martín JLF, López NC, García SP, Montes CA, García MR, Luengas ILM, Álvarez ES, Arias LM, Carro BM, Virgala JM, González MG, Barreiro JML, Fontan MP, González AO, Barja LMC, Barreiro AS, Arias BP, Hernández ÁA, Pérez MP, Varela JC, Lechuga JA, Rodríguez CD, Murias MG, Iglesia AMBDL, Piñeiro PB, González ÁG, Eijo AC, Cachaza NC, González MV, Garrit JMC, Blanch NL, Martínez AMS, Val MH, BordignonDraibe J, Melilli E, Montero AM, Pérez NM, Oliveras XF, Barrio MC, Santos JP, Barrera CB, Sáez MJP, Pachón MDR, Cabrales CA, Porras AB, García ER, Atxer LS, González VP, Mallol LL, Oliva MR, Puyol DR, Torres MPR, Ongil SL, Basilio LC, Centenera GO, Miguel PMD, Rodríguez LF, Nadah HB, Fernández MP, Chamond MRR, Ortiz PS, Fernández NG, Boillos AB, Cenarruzabeitia NV, Seara MAF, Moreno IDDPM, Lavilla FJ, Torres A, Miranda DM, Hernández APR, Redondo EDB, Porrini E, Caso MDLÁC, Tamajón MLP, Hernández MR, Rebollo MSG, Mallen PD, González AÁ, Rinne AMG, Rodríguez RM, Torres SE, Sosa DÁ, Cabrera BE, Rodríguez NZ, Hernández AF, Gamboa MJR, Caso C, Angeles MDL, Tamajon P, Lourdes M, Hernandez MR, Rebollo G, Sagrario M, Mallen PD, Gonzalez A, Alejandra, Rinne G, Maria A, Rodriguez RM, Torres SE, Sosa DA, Cabrera BE, Rodiguez NZ, Hernandez AF, Gamboa R, Jose M, Bermejo MLG, Lucas MF, Moreno EC, Muñoz LS, Huertas SS, Serrano EMR, Muñoz MER, Toro LC, Agudo CPB, Álvarez CG, Portoles J, Marqués M, Rubio E, Sánchez-Sobrino B, García-Menéndez E, Fernández AL, Diezhandin MG, Benítez PR, González MÁGN, Gallardo ML, Juárez GMF, Martínez EG, Terente MP, Ribera AT, Escribano TC, Fontan FC, Fernández AS, Pérez - Monteoliva NRR, Huerta EL, Rodríguez GG, Hernández SB, Zamorano SM, Gómez JML, Gallego RH. RICORS2040: the need for collaborative research in chronic kidney disease. Clin Kidney J 2021; 15:372-387. [PMID: 35211298 PMCID: PMC8862113 DOI: 10.1093/ckj/sfab170] [Citation(s) in RCA: 41] [Impact Index Per Article: 13.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Grants] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/12/2021] [Indexed: 01/17/2023] Open
Abstract
Abstract
Chronic kidney disease (CKD) is a silent and poorly known killer. The current concept of CKD is relatively young and uptake by the public, physicians and health authorities is not widespread. Physicians still confuse CKD with chronic kidney insufficiency or failure. For the wider public and health authorities, CKD evokes kidney replacement therapy (KRT). In Spain, the prevalence of KRT is 0.13%. Thus health authorities may consider CKD a non-issue: very few persons eventually need KRT and, for those in whom kidneys fail, the problem is ‘solved’ by dialysis or kidney transplantation. However, KRT is the tip of the iceberg in the burden of CKD. The main burden of CKD is accelerated ageing and premature death. The cut-off points for kidney function and kidney damage indexes that define CKD also mark an increased risk for all-cause premature death. CKD is the most prevalent risk factor for lethal coronavirus disease 2019 (COVID-19) and the factor that most increases the risk of death in COVID-19, after old age. Men and women undergoing KRT still have an annual mortality that is 10- to 100-fold higher than similar-age peers, and life expectancy is shortened by ~40 years for young persons on dialysis and by 15 years for young persons with a functioning kidney graft. CKD is expected to become the fifth greatest global cause of death by 2040 and the second greatest cause of death in Spain before the end of the century, a time when one in four Spaniards will have CKD. However, by 2022, CKD will become the only top-15 global predicted cause of death that is not supported by a dedicated well-funded Centres for Biomedical Research (CIBER) network structure in Spain. Realizing the underestimation of the CKD burden of disease by health authorities, the Decade of the Kidney initiative for 2020–2030 was launched by the American Association of Kidney Patients and the European Kidney Health Alliance. Leading Spanish kidney researchers grouped in the kidney collaborative research network Red de Investigación Renal have now applied for the Redes de Investigación Cooperativa Orientadas a Resultados en Salud (RICORS) call for collaborative research in Spain with the support of the Spanish Society of Nephrology, Federación Nacional de Asociaciones para la Lucha Contra las Enfermedades del Riñón and ONT: RICORS2040 aims to prevent the dire predictions for the global 2040 burden of CKD from becoming true.
Collapse
|
14
|
Kouroupis D, Lanzoni G, Linetsky E, Messinger Cayetano S, Wishnek Metalonis S, Leñero C, Stone LD, Ruiz P, Correa D, Ricordi C. Umbilical Cord-derived Mesenchymal Stem Cells modulate TNF and soluble TNF Receptor 2 (sTNFR2) in COVID-19 ARDS patients. Eur Rev Med Pharmacol Sci 2021; 25:4435-4438. [PMID: 34227081 DOI: 10.26355/eurrev_202106_26156] [Citation(s) in RCA: 11] [Impact Index Per Article: 3.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Subscribe] [Scholar Register] [Indexed: 11/12/2022]
Abstract
OBJECTIVE We aimed at explaining the mechanism of therapeutic effect of Umbilical Cord Mesenchymal Stem Cells (UC-MSC) in subjects with COVID-19 Acute Respiratory Distress Syndrome (ARDS). Patients with COVID-19 ARDS present with a hyperinflammatory response characterized by high levels of circulating pro-inflammatory mediators, including tumor necrosis factor α and β (TNFα and TNFβ). Inflammatory functions of these TNFs can be inhibited by soluble TNF Receptor 2 (sTNFR2). In patients with COVID-19 ARDS, UC-MSC appear to impart a robust anti-inflammatory effect, and treatment is associated with remarkable clinical improvements. We investigated the levels of TNFα, TNFβ and sTNFR2 in blood plasma samples collected from subjects with COVID-19 ARDS enrolled in our trial of UC-MSC treatment. PATIENTS AND METHODS We analyzed plasma samples from subjects with COVID-19 ARDS (n=24) enrolled in a Phase 1/2a randomized controlled trial of UC-MSC treatment. Plasma samples were obtained at Day 0 (baseline, before UC-MSC or control infusion), and Day 6 post infusion. Plasma concentrations of sTNFR2, TNFα, and TNFβ were evaluated using a quantitative multiplex protein array. RESULTS Our data indicate that at Day 6 after infusion, UC-MSC recipients develop significantly increased levels of plasma sTNFR2 and significantly decreased levels of TNFα and TNFβ, compared to controls. CONCLUSIONS These observations suggest that sTNFR2 plays a mechanistic role in mediating UC-MSC effect on TNFα and TNFβ plasma levels, determining a decrease in inflammation in COVID-19 ARDS.
Collapse
Affiliation(s)
- D Kouroupis
- Department of Orthopedics, UHealth Sports Medicine Institute, University of Miami Miller School of Medicine, Miami, FL, USA.
| | | | | | | | | | | | | | | | | | | |
Collapse
|
15
|
Mathew B, Ruiz P, Dutta S, Entrekin JT, Zhang S, Patel KD, Simmons MS, Augelli-Szafran CE, Cowell RM, Suto MJ. Structure-activity relationship (SAR) studies of N-(3-methylpyridin-2-yl)-4-(pyridin-2-yl)thiazol-2-amine (SRI-22819) as NF-ҡB activators for the treatment of ALS. Eur J Med Chem 2020; 210:112952. [PMID: 33139114 DOI: 10.1016/j.ejmech.2020.112952] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 08/20/2020] [Revised: 10/18/2020] [Accepted: 10/19/2020] [Indexed: 11/25/2022]
Abstract
ALS is a rare type of progressive neurological disease with unknown etiology. It results in the gradual degeneration and death of motor neurons responsible for controlling the voluntary muscles. Identification of mutations in the superoxide dismutase (SOD) 1 gene has been the most significant finding in ALS research. SOD1 abnormalities have been associated with both familial as well as sporadic ALS cases. SOD2 is a highly inducible SOD that performs in concurrence with SOD1 to detoxify ROS. Induction of SOD2 can be obtained through activation of NF-ҡBs. We previously reported that SRI-22819 increases NF-ҡB expression and activation in vitro, but it has poor ADME properties in general and has no oral bioavailability. Our initial studies were focused on direct modifications of SRI-22819. There were active compounds identified but no improvement in microsomal stability was observed. In this context, we focused on making more significant structural changes in the core of the molecule. Ataluren, an oxadiazole compound that promotes read-through and expression of dystrophin in patients with Duchenne muscular dystrophy, bears some structural similarity to SRI-22819. Thus, we synthesized a series of SRI-22819 and Ataluren (PTC124) hybrid compounds. Several compounds from this series exhibited improved activity, microsomal stability and lower calculated polar surface area (PSA). This manuscript describes the synthesis and biological evaluation of SRI-22819 analogs and its hybrid combination with Ataluren.
Collapse
Affiliation(s)
- Bini Mathew
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
| | - Pedro Ruiz
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
| | - Shilpa Dutta
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
| | - Jordan T Entrekin
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA
| | - Sixue Zhang
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA
| | - Kaval D Patel
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA
| | - Micah S Simmons
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA
| | - Corinne E Augelli-Szafran
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
| | - Rita M Cowell
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
| | - Mark J Suto
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL, 35205, USA.
| |
Collapse
|
16
|
Heredia Soto V, Pellinen T, Turkki R, Ramón Patiño J, Ruz-Caracuel I, García de la Calle L, López Janeiro Á, Escudero F, Miguel M, Crespo R, Ruiz P, Peláez-García A, Hardisson D, Redondo A, Mendiola M. 862P Prognostic role of CD3, CD4, CD8 and FOXP3 positive populations in early-stage endometrial carcinoma. Ann Oncol 2020. [DOI: 10.1016/j.annonc.2020.08.1001] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/28/2022] Open
|
17
|
Pani PP, Maremmani AGI, Pacini M, Trogu E, Gessa GL, Ruiz P, Maremmani I. Delineating the Psychic Structure of Substance Use and Addictions, from Neurobiology to Clinical Implications: Ten Years Later. J Clin Med 2020; 9:jcm9061913. [PMID: 32570932 PMCID: PMC7356689 DOI: 10.3390/jcm9061913] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/27/2020] [Revised: 06/12/2020] [Accepted: 06/16/2020] [Indexed: 11/16/2022] Open
Abstract
The diagnosis of substance use disorder is currently based on the presence of specifically identified behavioral symptoms. In addition, other psychiatric signs and symptoms accompany addictive behavior, contributing to the full picture of patients’ psychopathologic profile. Historically, such symptoms were confined within the framework of “comorbidity”, as comorbid psychiatric disorders or personality traits. However, an alternative unitary view of the psychopathology of addiction, inclusive of related psychiatric symptoms, has been claimed, with the support of epidemiological, neurobiological, and neuropsychological evidence. In the present article, we highlight the research advancements that strengthen this unified perspective. We then give an account of our group’s definition of a specific SCL-90-based construct of the psychopathology of addiction. Lastly, we discuss the benefits that can be expected to be acquired in the evaluation and treatment of patients with a longitudinal approach including psychological/psychiatric predisposing features, addictive behavior, and psychiatric manifestations.
Collapse
Affiliation(s)
- Pier Paolo Pani
- Social-Health Services, Azienda Tutela Salute Sardegna (Sardinia Health Trust), 09128 Cagliari, Italy;
| | - Angelo G. I. Maremmani
- Department of Psychiatry, North-Western Tuscany Local Health Unit, Tuscany NHS, Versilia Zone, 55049 Viareggio, Italy;
- Association for the Application of Neuroscientific Knowledge to Social Aims (AU-CNS), 55045 Pietrasanta, Italy
- PISA-School of Experimental and Clinical Psychiatry, 56100 Pisa, Italy
| | - Matteo Pacini
- G. De Lisio Institute of Behavioral Sciences, 56100 Pisa, Italy;
| | | | - Gian Luigi Gessa
- Emeritus of Neuropharmacology, University of Cagliari, 09124 Cagliari, Italy;
| | - Pedro Ruiz
- Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston, TX 77030, USA;
| | - Icro Maremmani
- PISA-School of Experimental and Clinical Psychiatry, 56100 Pisa, Italy
- G. De Lisio Institute of Behavioral Sciences, 56100 Pisa, Italy;
- Vincent P. Dole Dual Disorder Unit, 2nd Psychiatric Unit, Santa Chiara University Hospital, University of Pisa, 56100 Pisa, Italy
- Correspondence: ; Tel.: +39-050-993045
| |
Collapse
|
18
|
Lanzoni G, Linetsky E, Correa D, Alvarez RA, Marttos A, Hirani K, Cayetano SM, Castro JG, Paidas MJ, Efantis Potter J, Xu X, Glassberg M, Tan J, Patel AN, Goldstein B, Kenyon NS, Baidal D, Alejandro R, Vianna R, Ruiz P, Caplan AI, Ricordi C. Umbilical Cord-derived Mesenchymal Stem Cells for COVID-19 Patients with Acute Respiratory Distress Syndrome (ARDS). CellR4 Repair Replace Regen Reprogram 2020; 8. [PMID: 34164564 DOI: 10.32113/cellr4_20204_2839] [Citation(s) in RCA: 4] [Impact Index Per Article: 1.0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Subscribe] [Scholar Register] [Indexed: 02/06/2023]
Abstract
The coronavirus SARS-CoV-2 is cause of a global pandemic of a pneumonia-like disease termed Coronavirus Disease 2019 (COVID-19). COVID-19 presents a high mortality rate, estimated at 3.4%. More than 1 out of 4 hospitalized COVID-19 patients require admission to an Intensive Care Unit (ICU) for respiratory support, and a large proportion of these ICU-COVID-19 patients, between 17% and 46%, have died. In these patients COVID-19 infection causes an inflammatory response in the lungs that can progress to inflammation with cytokine storm, Acute Lung Injury (ALI), Acute Respiratory Distress Syndrome (ARDS), thromboembolic events, disseminated intravascular coagulation, organ failure, and death. Mesenchymal Stem Cells (MSCs) are potent immunomodulatory cells that recognize sites of injury, limit effector T cell reactions, and positively modulate regulatory cell populations. MSCs also stimulate local tissue regeneration via paracrine effects inducing angiogenic, anti-fibrotic and remodeling responses. MSCs can be derived in large number from the Umbilical Cord (UC). UC-MSCs, utilized in the allogeneic setting, have demonstrated safety and efficacy in clinical trials for a number of disease conditions including inflammatory and immune-based diseases. UC-MSCs have been shown to inhibit inflammation and fibrosis in the lungs and have been utilized to treat patients with severe COVID-19 in pilot, uncontrolled clinical trials, that reported promising results. UC-MSCs processed at our facility have been authorized by the FDA for clinical trials in patients with an Alzheimer's Disease, and in patients with Type 1 Diabetes (T1D). We hypothesize that UC-MSC will also exert beneficial therapeutic effects in COVID-19 patients with cytokine storm and ARDS. We propose an early phase controlled, randomized clinical trial in COVID-19 patients with ALI/ARDS. Subjects in the treatment group will be treated with two doses of UC-MSC (l00 × 106 cells). The first dose will be infused within 24 hours following study enrollment. A second dose will be administered 72 ± 6 hours after the first infusion. Subject in the control group will receive infusion of vehicle (DPBS supplemented with 1% HSA and 70 U/kg unfractionated Heparin, delivered IV) following the same timeline. Subjects will be evaluated daily during the first 6 days, then at 14, 28, 60, and 90 days following enrollment (see Schedule of Assessment for time window details). Safety will be determined by adverse events (AEs) and serious adverse events (SAEs) during the follow-up period. Efficacy will be defined by clinical outcomes, as well as a variety of pulmonary, biochemical and immunological tests. Success of the current study will provide a framework for larger controlled, randomized clinical trials and a means of accelerating a possible solution for this urgent but unmet medical need. The proposed early phase clinical trial will be performed at the University of Miami (UM), in the facilities of the Diabetes Research Institute (DRI), UHealth Intensive Care Unit (ICU) and the Clinical Translational Research Site (CTRS) at the University of Miami Miller School of Medicine and at the Jackson Memorial Hospital (JMH).
Collapse
Affiliation(s)
- G Lanzoni
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Biochemistry and Molecular Biology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - E Linetsky
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - D Correa
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Orthopedics, University of Miami Miller School of Medicine, Miami, FL, USA
| | - R A Alvarez
- University of Miami Health System and Jackson Health System, Miami, FL, USA.,Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - A Marttos
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.,University of Miami Health System and Jackson Health System, Miami, FL, USA
| | - K Hirani
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - S Messinger Cayetano
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department Public Health Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - J G Castro
- University of Miami Health System and Jackson Health System, Miami, FL, USA.,Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - M J Paidas
- University of Miami Health System and Jackson Health System, Miami, FL, USA.,Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - J Efantis Potter
- Department of Obstetrics, Gynecology and Reproductive Sciences, University of Miami Miller School of Medicine, Miami, FL, USA
| | - X Xu
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA
| | - M Glassberg
- Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA
| | - J Tan
- Organ Transplant Institute, Fuzhou General Hospital, Xiamen University, Fuzhou, China
| | - A N Patel
- Department of Biomedical Engineering, University of Utah, Salt Lake City, UT, USA.,HCA Research Institute, Nashville, TN, USA
| | - B Goldstein
- Department of Head and Neck Surgery and Communication Sciences, Duke University, Durham, NC, USA
| | - N S Kenyon
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - D Baidal
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - R Alejandro
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Medicine, University of Miami Miller School of Medicine, Miami, Florida, USA
| | - R Vianna
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.,University of Miami Health System and Jackson Health System, Miami, FL, USA.,Miami Transplant Institute, Jackson Health System, Miami, FL, USA
| | - P Ruiz
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.,University of Miami Health System and Jackson Health System, Miami, FL, USA.,Miami Transplant Institute, Jackson Health System, Miami, FL, USA
| | - A I Caplan
- Department of Medicine, University of Arizona College of Medicine, Phoenix, AZ, USA
| | - C Ricordi
- Diabetes Research Institute, Cell Transplant Center, University of Miami Miller School of Medicine, Miami, FL, USA.,Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA.,University of Miami Health System and Jackson Health System, Miami, FL, USA
| |
Collapse
|
19
|
Mathew B, Ruiz P, Pathak V, Suto MJ. Development of novel small molecules for the treatment of ALS. Bioorg Med Chem Lett 2020; 30:126950. [PMID: 31928838 DOI: 10.1016/j.bmcl.2020.126950] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.5] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/15/2019] [Revised: 12/19/2019] [Accepted: 01/01/2020] [Indexed: 12/12/2022]
Abstract
Amyotrophic lateral sclerosis (ALS) is a rare and progressive neurodegenerative disease with unknown etiology. It is caused by the degeneration of motor neurons responsible for controlling voluntary muscles. It has been reported that mutations in the superoxide dismutase (SOD) 1 gene can lead to ALS. SOD1 abnormalities have been identified in both familial, as well as sporadic ALS cases. SOD2 is a highly inducible SOD that works in conjunction with SOD1. SOD2 can be induced through activation of NF-κBs. We previously reported that the novel small molecule, SRI-22818, increases NF-κB expression and activation and SOD2 levels in vitro and has activity in vivo in the SOD1-G93A reference model of ALS. We report herein the synthesis and biological evaluation of SRI-22818 analogs.
Collapse
Affiliation(s)
- Bini Mathew
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Pedro Ruiz
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Vibha Pathak
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA
| | - Mark J Suto
- Drug Discovery Division, Southern Research Institute, 2000 Ninth Avenue South, Birmingham, AL 35205, USA.
| |
Collapse
|
20
|
Mendiola M, Heredia-Soto V, Escudero J, Crespo R, Ruiz P, Martínez AG, Martínez-Marin V, Pozo J, Berjón A, Ortiz-Cruz E, Bernabeu D, Redondo A. Influence of eribulin on proliferation, migration and invasion properties of leiomyosarcoma cell line models. Ann Oncol 2019. [DOI: 10.1093/annonc/mdz283.063] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
|
21
|
Coughlin S, Bahaadini S, Rohani N, Zevin M, Patane O, Harandi M, Jackson C, Noroozi V, Allen S, Areeda J, Coughlin M, Ruiz P, Berry C, Crowston K, Katsaggelos A, Lundgren A, Østerlund C, Smith J, Trouille L, Kalogera V. Classifying the unknown: Discovering novel gravitational-wave detector glitches using similarity learning. Int J Clin Exp Med 2019. [DOI: 10.1103/physrevd.99.082002] [Citation(s) in RCA: 24] [Impact Index Per Article: 4.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/07/2022]
|
22
|
González-Medina G, Ruiz P, Guia D, Bueno G, Vega R, Martins A. Risk of fall: a preliminary study to understand the differences between Portuguese and Spanish community dwelling adults aged 50 or over to develop an action plan for an effective fall prevention. Eur J Public Health 2019. [DOI: 10.1093/eurpub/ckz034.092] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/12/2022] Open
Affiliation(s)
| | - P Ruiz
- Nursing and Physiotherapy Department, University of Cádiz, Spain
| | - D Guia
- ESTeSC - Coimbra Health School, Instituto Politécnico de Coimbra, Portugal
| | - G Bueno
- ESTeSC - Coimbra Health School, Instituto Politécnico de Coimbra, Portugal
- University of Brasilia, Brazil
| | - R Vega
- Health Sciences Department, University of Jaén, Spain
| | - A Martins
- ESTeSC - Coimbra Health School, Instituto Politécnico de Coimbra, Portugal
| |
Collapse
|
23
|
Rodríguez A, Tajuelo M, Rodríguez D, Seseña S, Ruiz P, Palop ML. Assessment of chemical and microbiological parameters of indoor swimming pool atmosphere using multiple comparisons. Indoor Air 2018; 28:676-688. [PMID: 29873109 DOI: 10.1111/ina.12477] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/28/2017] [Accepted: 06/03/2018] [Indexed: 06/08/2023]
Abstract
The aim of this study was to evaluate the air quality of an indoor swimming pool, analyzing diurnal and seasonal variations in microbiological counts and chemical parameters. The results indicated that yeast and bacteria counts, as well as carbon dioxide (CO2 ), nitrogen oxides (NOx ) and O3 concentrations, showed significant diurnal difference. On the other hand, temperature, relative humidity (R.H.), yeast counts and concentrations of CO2 , particles, O3 , toluene, and benzene showed seasonal differences. In addition, the relationship between indoor and outdoor air and the degree of correlation between the different parameters have been calculated, suggesting that CO2 , fine particles and NOx would have indoor origin due to the human activity and secondary reactions favored by the chemical and environmental conditions of the swimming pool; while O3 , benzene and toluene, would come from outside, mainly. The overall results indicated that indoor air quality (IAQ) in the swimming pool building was deficient by the high levels of CO2 and microorganisms, low temperatures, and high R.H., because frequently the limits established by the legislation were exceeded. This fact could be due to the poor ventilation and the inadequate operation of heating, ventilation, and air-conditioning systems.
Collapse
Affiliation(s)
- A Rodríguez
- Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain
| | - M Tajuelo
- Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain
| | - D Rodríguez
- Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain
| | - S Seseña
- Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain
| | - P Ruiz
- Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain
| | - M Ll Palop
- Faculty of Environmental Sciences and Biochemistry, University of Castilla-La Mancha, Toledo, Spain
| |
Collapse
|
24
|
Simkins J, Anjan S, Morillas-Rodriguez JA, Greissman SR, Abbo LM, Camargo JF, Ruiz P, Vianna R, Guerra G, Salama S, Morris MI. Screening for Zika virus in deceased organ donors in Florida. Am J Transplant 2018; 18:731-736. [PMID: 29116671 DOI: 10.1111/ajt.14582] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/11/2017] [Revised: 10/19/2017] [Accepted: 10/22/2017] [Indexed: 01/25/2023]
Abstract
Zika virus (ZIKV) cases have been detected across the United States (US) and locally acquired cases have been reported in Florida. Currently, there are no ZIKV screening guidelines and no data on the incidence among organ donors in the US. This retrospective study was conducted at Jackson Memorial-Miami Transplant Institute. Positive ZIKV tests in local deceased organ donors were investigated from 6/2016 to 1/2017. We evaluated demographics and risk factors for ZIKV infection among organ donors and transplant outcomes among recipients of donors with positive ZIKV testing. One hundred forty-two donors were analyzed. Ten percent had traveled to ZIKV-endemic countries and 19% had outdoor occupations. Only 3% had positive ZIKV IGG. None had a positive ZIKV IGM or PCR. ZIKV-positive donors were more likely to have traveled to ZIKV-endemic countries (50% vs. 9%, P = .05). The kidneys from a ZIKV-positive donor were transplanted in our hospital with no 6-month rejection, graft failure, or death in the recipients. Our study demonstrated a low prevalence of ZIKV among deceased donors in our community. Despite local ZIKV transmission, ZIKV was more common in donors who traveled to ZIKV-endemic countries. This cohort demonstrated excellent outcomes in recipients of ZIKV IGG-positive donors. However, larger studies are needed.
Collapse
Affiliation(s)
- J Simkins
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - S Anjan
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | | | - S R Greissman
- University of Miami Miller School of Medicine, Miami, FL, USA
| | - L M Abbo
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - J F Camargo
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - P Ruiz
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - R Vianna
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - G Guerra
- Division of Nephrology, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - S Salama
- Department of Surgery, University of Miami Miller School of Medicine, Miami, FL, USA
| | - M I Morris
- Division of Infectious Diseases, Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| |
Collapse
|
25
|
Calquín P, Ruiz P, Oliver C, Sánchez P, Haro R, Oliva H, Vargas-Chacoff L, Avendaño-Herrera R, Yáñez AJ. Physiological evidence that Piscirickettsia salmonis produces siderophores and uses iron from different sources. J Fish Dis 2018; 41:553-558. [PMID: 29193147 DOI: 10.1111/jfd.12745] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 06/15/2017] [Revised: 09/16/2017] [Accepted: 09/24/2017] [Indexed: 06/07/2023]
Affiliation(s)
- P Calquín
- Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile
- Interdisciplinary Center for Aquaculture Research (INCAR), Concepción, Chile
| | - P Ruiz
- Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile
- Interdisciplinary Center for Aquaculture Research (INCAR), Concepción, Chile
| | - C Oliver
- Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile
- Interdisciplinary Center for Aquaculture Research (INCAR), Concepción, Chile
- Laboratorio de Patología de Organismos Acuáticos y Biotecnología Acuícola, Facultad de Ciencias Biológicas, Universidad Andrés Bello, Viña del Mar, Chile
| | - P Sánchez
- Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile
- Interdisciplinary Center for Aquaculture Research (INCAR), Concepción, Chile
| | - R Haro
- Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile
| | - H Oliva
- Veterquímica S.A., Cerrillos, Santiago, Chile
| | - L Vargas-Chacoff
- Instituto de Ciencias Marinas y Limnológicas, Universidad Austral de Chile, Valdivia, Chile
- Centro Fondap de Investigación de Altas Latitudes (IDEAL), Universidad Austral de Chile, Valdivia, Chile
| | - R Avendaño-Herrera
- Interdisciplinary Center for Aquaculture Research (INCAR), Concepción, Chile
- Laboratorio de Patología de Organismos Acuáticos y Biotecnología Acuícola, Facultad de Ciencias Biológicas, Universidad Andrés Bello, Viña del Mar, Chile
- Centro de Investigación Marina Quintay (CIMARQ), Quintay, Chile
| | - A J Yáñez
- Facultad de Ciencias, Instituto de Bioquímica y Microbiología, Universidad Austral de Chile, Valdivia, Chile
- Interdisciplinary Center for Aquaculture Research (INCAR), Concepción, Chile
- Austral-OMICS, Facultad de Ciencias, Universidad Austral de Chile, Valdivia, Chile
| |
Collapse
|
26
|
Ohira M, Nishida S, Tryphonopoulos P, Ruiz P, Ohdan H, Tzakis AG. Impact of Steroids on Natural Killer Cells Against Cytotoxicity and Hepatitis C Virus Replication. Transplant Proc 2018; 49:1160-1164. [PMID: 28583548 DOI: 10.1016/j.transproceed.2017.03.018] [Citation(s) in RCA: 7] [Impact Index Per Article: 1.2] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/19/2022]
Abstract
BACKGROUND Natural killer (NK) cells play important roles in killing tumor and virus-infected cells. Immunosuppression used after organ transplantation is thought to increase the risk of tumor recurrence and viral infections. However, the effect of immunosuppressive drugs on NK cells has not yet been clearly established. Therefore, we examined the effect of immunosuppression on NK cells. METHODS NK cells were cultured for 7 days in the presence of interleukin-2 (100 U/mL) with or without the following immunosuppressive drugs: tacrolimus, cyclosporine A, corticosteroid (methylprednisolone [MP]), mycophenolate mofetil, and rapamycin. The effect of the drugs on NK cell activation was tested on the basis of the following: NK cell phenotype, NK cell proliferation, cytotoxicity against K562 cells, cytokine production by NK cells, and anti-hepatitis C virus (HCV) activity with HCV genomic replicon cells. RESULTS NK cells showed relatively robust functions in the presence of tacrolimus and cyclosporine A. Mycophenolate mofetil and rapamycin significantly prevented only NK cell proliferation (P < .05). In contrast, MP significantly inhibited the proliferation, cytotoxicity, and anti-HCV effect (10.9%, 18.5%, and 1.9%, respectively) of NK cells. Furthermore, MP specifically inhibited the expression of NK cell activation markers and the production of interferon-γ (P < .05). CONCLUSIONS Corticosteroids have distinct effects on NK cells, which may have important implications for NK cell function in cytotoxicity and HCV effect after transplantation.
Collapse
Affiliation(s)
- M Ohira
- Department of Surgery, Division of Liver and Gastrointestinal Transplantation, University of Miami Miller School of Medicine, Miami, Florida; Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - S Nishida
- Department of Surgery, Division of Liver and Gastrointestinal Transplantation, University of Miami Miller School of Medicine, Miami, Florida.
| | - P Tryphonopoulos
- Department of Surgery, Division of Liver and Gastrointestinal Transplantation, University of Miami Miller School of Medicine, Miami, Florida
| | - P Ruiz
- Department of Pathology and Surgery, University of Miami Miller School of Medicine, Miami, Florida
| | - H Ohdan
- Gastroenterological and Transplant Surgery, Applied Life Sciences, Institute of Biomedical & Health Sciences, Hiroshima University, Hiroshima, Japan
| | - A G Tzakis
- Department of Surgery, Division of Liver and Gastrointestinal Transplantation, University of Miami Miller School of Medicine, Miami, Florida; Department of Surgery, Cleveland Clinic Florida, Weston, Florida
| |
Collapse
|
27
|
Abstract
The association between ethnicity and pharmacology has been reported in the medical literature for several decades. However, the relationship between ethnicity and psychopharmacology has become widely recognised only in the last two or three decades. The large-scale migration which started after the Second World War, at first to the USA and more recently to other higher-income countries, as a result of globalisation, has greatly contributed to the attention and focus given to these migrant groups. In this context, these migrant groups primarily comprise ethnic and racial minority groups. This article briefly reviews the relationship between ethnicity and psychopharmacological agents.
Collapse
|
28
|
Lombardo-Quezada J, Sanclemente G, Colmenero J, Español-Rego M, Arias MT, Ruiz P, Mauro E, Sastre L, Crespo G, Rimola A, Moreno A, Lozano F, Navasa M. Mannose-Binding Lectin-Deficient Donors Increase the Risk of Bacterial Infection and Bacterial Infection-Related Mortality After Liver Transplantation. Am J Transplant 2018; 18:197-206. [PMID: 28649744 DOI: 10.1111/ajt.14408] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/15/2017] [Revised: 05/23/2017] [Accepted: 06/13/2017] [Indexed: 01/25/2023]
Abstract
Mannose-binding lectin (MBL) is synthesized by the liver and binds to microbes. MBL2 gene polymorphisms produce intermediate/low/null or normal MBL serum levels (MBL-deficient or MBL-sufficient phenotypes, respectively). We aimed to evaluate the incidence and severity of infection, rejection, and survival within 1 year after liver transplantation (LT) according to donor and recipient MBL2 gene polymorphisms. A repeated-event analysis for infection episodes (negative binomial regression, Andersen-Gill model) was performed in 240 LTs. Four hundred twenty-eight infectious episodes (310 bacterial, 15 fungal, 65 cytomegalovirus [CMV]-related, and 38 viral non-CMV-related episodes) and 48 rejection episodes were recorded. The main bacterial infections were urinary (n = 82, 26%) and pneumonia (n = 69, 22%). LT recipients of MBL-deficient livers had a higher risk of bacterial infection (incidence rate ratio [IRR] 1.48 [95% confidence interval 1.04-2.09], p = 0.028), pneumonia (IRR 2.4 [95% confidence interval 1.33-4.33], p = 0.013), and septic shock (IRR 5.62 [95% confidence interval 1.92-16.4], p = 0.002) compared with recipients of MBL-deficient livers. The 1-year bacterial infection-related mortality was higher in recipients of MBL-deficient versus MBL-sufficient livers (65.8% vs. 56.1%, respectively; p = 0.0097). The incidence of rejection, viral, or fungal infection was similar in both groups. Recipient MBL2 genotype did not significantly increase the risk of bacterial infection. LT recipients of MBL-deficient livers have a higher risk of bacterial infection, pneumonia, septic shock, and 1-year bacterial infection-related mortality after LT.
Collapse
Affiliation(s)
- J Lombardo-Quezada
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - G Sanclemente
- Infectious Diseases Department, REIPI, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - J Colmenero
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - M Español-Rego
- Immunology Department, Center of Biomedical Diagnosis, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - M T Arias
- Immunology Department, Center of Biomedical Diagnosis, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - P Ruiz
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - E Mauro
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - L Sastre
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - G Crespo
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - A Rimola
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - A Moreno
- Infectious Diseases Department, REIPI, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - F Lozano
- Immunology Department, Center of Biomedical Diagnosis, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| | - M Navasa
- Liver Transplant Unit, CIBERehd, Barcelona, Spain.,Hospital Clínic, Institut d'Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), University of Barcelona, Barcelona, Spain
| |
Collapse
|
29
|
Szerman N, Martínez-Raga J, Baler R, Roncero C, Vega P, Basurte I, Grau-López L, Torrens, M, Casas M, Franco C, Spinnato G, Maremmani I, Maremmani AGI, Daulouède JP, Aguerretxe-Colina A, Mann K, Marín-Navarrete R, Medina-Mora ME, Ruiz P. Joint statement on dual disorders: Addiction and other mental disorders. sm 2017. [DOI: 10.17711/sm.0185-3325.2017.031] [Citation(s) in RCA: 8] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Abstract] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 11/17/2022]
|
30
|
López-Herradón A, Fujikawa R, Gómez-Marín M, Stedile-Lovatel JP, Mulero F, Ardura JA, Ruiz P, Muñoz I, Esbrit P, Mahíllo-Fernández I, Ortega-de Mues A. Impact of Chiropractic Manipulation on Bone and Skeletal Muscle of Ovariectomized Rats. Calcif Tissue Int 2017; 101:519-529. [PMID: 28755011 DOI: 10.1007/s00223-017-0304-1] [Citation(s) in RCA: 4] [Impact Index Per Article: 0.6] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 05/03/2017] [Accepted: 07/12/2017] [Indexed: 01/01/2023]
Abstract
Evidence suggests that chiropractic manipulation might exert positive effects in osteoporotic patients. The aim of this study was to evaluate the effects of chiropractic manipulation on bone structure and skeletal muscle in rats with bone loss caused by ovariectomy (OVX). The 6-month old Sprague-Dawley rats at 10 weeks following OVX or sham operation (Sh) did not suffer chiropractic manipulation (NM group) or were submitted to true chiropractic manipulation using the chiropractic adjusting instrument Activator V® three times/week for 6 weeks as follows: Force 1 setting was applied onto the tibial tubercle of the rat right hind limb (TM group), whereas the corresponding left hind limb received a false manipulation (FM group) consisting of ActivatorV® firing in the air and slightly touching the tibial tubercle. Bone mineral density (BMD) and bone mineral content (BMC) were determined in long bones and L3-L4 vertebrae in all rats. Femora and tibia were analyzed by μCT. Mechano growth factor (MGF) was detected in long bones and soleus, quadriceps and tibial muscles by immunohistochemistry and Western blot. The decrease of BMD and BMC as well as trabecular bone impairment in the long bones of OVX rats vs Sh controls was partially reversed in the TM group versus FM or NM rats. This bone improvement by chiropractic manipulation was associated with an increased MGF expression in the quadriceps and the anterior tibial muscle in OVX rats. These findings support the notion that chiropractic manipulation can ameliorate osteoporotic bone at least partly by targeting skeletal muscle.
Collapse
Affiliation(s)
- A López-Herradón
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain
- Laboratorio de Metabolismo Mineral y Óseo, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz-UAM, Madrid, Spain
| | - R Fujikawa
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain
| | - M Gómez-Marín
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain
| | - J P Stedile-Lovatel
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain
| | - F Mulero
- Unidad de Imagen Molecular, Centro Nacional de Investigaciones Oncológicas (CNIO), Madrid, Spain
| | - J A Ardura
- Laboratorio de Metabolismo Mineral y Óseo, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz-UAM, Madrid, Spain
| | - P Ruiz
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain
| | - I Muñoz
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain
| | - P Esbrit
- Laboratorio de Metabolismo Mineral y Óseo, Instituto de Investigación Sanitaria (IIS)-Fundación Jiménez Díaz-UAM, Madrid, Spain
| | - I Mahíllo-Fernández
- Unidad de Epidemiología y Bioestadística, IIS-Fundación Jiménez Díaz-UAM, Madrid, Spain
| | - A Ortega-de Mues
- Madrid College of Chiropractic, Real Centro Universitario Escorial-María Cristina, Paseo de los Alamillos, 2, San Lorenzo de El Escorial, 28200, Madrid, Spain.
| |
Collapse
|
31
|
Affiliation(s)
- Pedro Ruiz
- Dr. Ruiz is president of the World Association on Dual Disorders (WADD) and clinical professor of the Menninger Department of Psychiatry and Behavioral Sciences, Baylor College of Medicine, Houston
| |
Collapse
|
32
|
Muñoz J, Soblechero P, Duque FJ, Macías-García B, Ruiz P, Zaragoza C, Barrera R. Effects of Oral Prednisone Administration on Serum Cystatin C in Dogs. J Vet Intern Med 2017; 31:1765-1770. [PMID: 28921665 PMCID: PMC5697201 DOI: 10.1111/jvim.14820] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Download PDF] [Figures] [Journal Information] [Subscribe] [Scholar Register] [Received: 03/14/2017] [Revised: 06/20/2017] [Accepted: 08/01/2017] [Indexed: 11/27/2022] Open
Abstract
Background Oral administration of glucocorticoid alters serum cystatin C (sCysC) concentration in humans. Objective To determine if oral administration of prednisone alters sCysC in dogs without pre‐existing renal disease. Animals Forty six dogs were included: 10 dogs diagnosed with steroid responsive meningitis arteritis (SRMA; group A), 20 dogs diagnosed of pituitary‐dependent hyperadrenocorticism (PDH; group B), and 16 healthy control dogs (group C). Methods Retrospective observational study. SRMA diagnosed dogs were administered prednisone 4 mg/kg/24 h PO 7 days, reducing the dose to 2 mg/kg/24 h 7 days before medication withdrawal. In group A, sampling was performed at days 0, 7, 14 and a final control at day 21. Blood and urine samples were collected in the 3 groups, and in group A, sampling was performed at all time points (days 1, 7, 14, and 21). Results In group A, sCysC was significantly higher at day 7 compared to the control group (0.4 ± 0.04 mg/L vs. 0.18 ± 0.03 mg/L mean ± SEM respectively P < 0.01); sCysC values decreased to basal at day 14 when the dose was decreased and after 1 week of withdrawal of prednisone (0.27 ± 0.03 mg/L for group A at day 14 and 0.15 ± 0.02 mg/L at day 21; P > 0.05). Dogs with PDH included in group B did not have significant differences in sCysC (0.22 ± 0.03 mg/L) compared to control (P > 0.05). Conclusions and Clinical Importance Oral administration of prednisone unlike altered endogenous glucocorticoid production, increases sCysC in dogs in a dose‐dependent fashion.
Collapse
Affiliation(s)
- J Muñoz
- Animal Medicine Department, Faculty of Veterinary Sciences, University of Extremadura, Cáceres, Spain
| | - P Soblechero
- Animal Medicine Department, Faculty of Veterinary Sciences, University of Extremadura, Cáceres, Spain
| | - F J Duque
- Animal Medicine Department, Faculty of Veterinary Sciences, University of Extremadura, Cáceres, Spain
| | - B Macías-García
- Assisted Reproduction Unit, Minimally Invasive Surgery Centre JesúsUsón, Cáceres, Spain
| | - P Ruiz
- Animal Medicine Department, Faculty of Veterinary Sciences, University of Extremadura, Cáceres, Spain
| | - C Zaragoza
- Animal Medicine Department, Faculty of Veterinary Sciences, University of Extremadura, Cáceres, Spain
| | - R Barrera
- Animal Medicine Department, Faculty of Veterinary Sciences, University of Extremadura, Cáceres, Spain
| |
Collapse
|
33
|
Del Blanco Á, Torrente J, Fernández-Manjón B, Ruiz P, Giner M. Using a videogame to facilitate nursing and medical students' first visit to the operating theatre. A randomized controlled trial. Nurse Educ Today 2017; 55:45-53. [PMID: 28521249 DOI: 10.1016/j.nedt.2017.04.026] [Citation(s) in RCA: 27] [Impact Index Per Article: 3.9] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 10/26/2016] [Revised: 03/21/2017] [Accepted: 04/28/2017] [Indexed: 06/07/2023]
Abstract
BACKGROUND First experiences in the operating theatre with real patients are always stressful and intimidating for students. We hypothesized that a game-like simulation could improve perceptions and performance of novices. METHODS A videogame was developed, combining pictures and short videos, by which students are interactively instructed on acting at the surgical block. Moreover, the game includes detailed descriptive information. After playing, students are given feedback on their performance. A randomized controlled trial was conducted with 132 nursing and medical students with no previous experience in surgery. Sixty two (47.0%) were allocated to a control group (CG) and 70 (53.0%) to an experimental group (EG). Subjects in EG played the game the day prior to their first experience in the theatre; CG had no access to the application. On the day after their experience at surgery, all students filled in a questionnaire in a 7-point Likert format collecting subjective data about their experience in the surgical block. Four constructs related to students' feelings, emotions and attitudes were measured through self-reported subjective scales, i.e. C1: fear to make mistakes, C2: perceived knowledge on how to behave, C3: perceived errors committed, and C4: attitude/behaviour towards patients and staff. The main research question was formulated as follows: do students show differences in constructs C1-C4 by exposure to the game? RESULTS EG reported statistically significant higher scores on the four aspects measured than CG (p<0.05; Mann-Whitney U tests; Cohen's d standardized effect size d1=0.30; d2=1.05; d3=0.39; d4=0.49). CONCLUSIONS Results show clear evidence that the exposure to the game-like simulation had a significant positive effect on all the constructs. After their first visit to the theatre, students in EG showed less fear (C1) and also perceived to have committed fewer errors (C3), while they showed higher perceived knowledge (C2) and a more collaborative attitude (C4).
Collapse
Affiliation(s)
- Ángel Del Blanco
- Department of Software and Artificial Intelligence, School of Informatics, Complutense University of Madrid, 28040 Madrid, Spain
| | - Javier Torrente
- Department of Software and Artificial Intelligence, School of Informatics, Complutense University of Madrid, 28040 Madrid, Spain
| | - Baltasar Fernández-Manjón
- Department of Software and Artificial Intelligence, School of Informatics, Complutense University of Madrid, 28040 Madrid, Spain
| | - Pedro Ruiz
- Department of Surgery, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain
| | - Manuel Giner
- Department of Surgery, School of Medicine, Complutense University of Madrid, 28040 Madrid, Spain.
| |
Collapse
|
34
|
Ruiz P, Sack A, Wampole M, Bobst S, Vracko M. Integration of in silico methods and computational systems biology to explore endocrine-disrupting chemical binding with nuclear hormone receptors. Chemosphere 2017; 178:99-109. [PMID: 28319747 PMCID: PMC8265162 DOI: 10.1016/j.chemosphere.2017.03.026] [Citation(s) in RCA: 10] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Received: 12/06/2016] [Revised: 03/06/2017] [Accepted: 03/07/2017] [Indexed: 05/30/2023]
Abstract
Thousands of potential endocrine-disrupting chemicals present difficult regulatory challenges. Endocrine-disrupting chemicals can interfere with several nuclear hormone receptors associated with a variety of adverse health effects. The U.S. Environmental Protection Agency (U.S. EPA) has released its reviews of Tier 1 screening assay results for a set of pesticides in the Endocrine Disruptor Screening Program (EDSP), and recently, the Collaborative Estrogen Receptor Activity Prediction Project (CERAPP) data. In this study, the predictive ability of QSAR and docking approaches is evaluated using these data sets. This study also presents a computational systems biology approach using carbaryl (1-naphthyl methylcarbamate) as a case study. For estrogen receptor and androgen receptor binding predictions, two commercial and two open source QSAR tools were used, as was the publicly available docking tool Endocrine Disruptome. For estrogen receptor binding predictions, the ADMET Predictor, VEGA, and OCHEM models (specificity: 0.88, 0.88, and 0.86, and accuracy: 0.81, 0.84, and 0.88, respectively) were each more reliable than the MetaDrug™ model (specificity 0.81 and accuracy 0.77). For androgen receptor binding predictions, the Endocrine Disruptome and ADMET Predictor models (specificity: 0.94 and 0.8, and accuracy: 0.78 and 0.71, respectively) were more reliable than the MetaDrug™ model (specificity 0.33 and accuracy 0.4). A consensus approach is proposed that reaches general agreement among the models (specificity 0.94 and accuracy 0.89). This study integrates QSAR, docking, and systems biology approaches as a virtual screening tool for use in risk assessment. As such, this systems biology pathways and network analysis approach provides a means to more critically assess the potential effects of endocrine-disrupting chemicals.
Collapse
Affiliation(s)
- P Ruiz
- Computational Toxicology and Methods Development Laboratory, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, GA, USA.
| | - A Sack
- Computational Toxicology and Methods Development Laboratory, Division of Toxicology and Human Health Sciences, Agency for Toxic Substances and Disease Registry, Atlanta, GA, USA
| | - M Wampole
- Thomson Reuters, Philadelphia, PA, USA
| | - S Bobst
- ToxSci Advisors, Houston, TX, USA
| | - M Vracko
- Kemijski Inštitut/National Institute of Chemistry, Hajdrihova 19, 1000, Ljubljana, Slovenia
| |
Collapse
|
35
|
Fernandez LA, Romaguera R, Viciana AL, Ruiz P, Tzakis AG, Ricordi C. Pulmonary Embolism with Bone Fragments following Vertebral Body Marrow Infusion for Tolerance Induction. Cell Transplant 2017; 5:513-6. [PMID: 8800520 DOI: 10.1177/096368979600500411] [Citation(s) in RCA: 2] [Impact Index Per Article: 0.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022] Open
Abstract
Protocols of donor bone marrow infusion for tolerance induction are receiving increasing attention in clinical trials of organ allotransplantation. We report pulmonary embolism with bone fragments following vertebral body marrow infusion in a recipient of a liver and intestinal transplant. Even though pulmonary embolism with bony microfragments has been widely described following bone marrow transplantation, the use of single, high-dose donor bone marrow infusion and/or multiple infusions currently under clinical investigation for induction of donor specific unresponsiveness, may warrant the implementation of additional steps in the vertebral body marrow processing technique to decrease or eliminate the component of bony microfragments in the final preparation.
Collapse
Affiliation(s)
- L A Fernandez
- Veterans Administration Medical Center, Division of Surgery, Miami, FL, USA
| | | | | | | | | | | |
Collapse
|
36
|
Gastaca M, Prieto M, Valdivieso A, Ruiz P, Ventoso A, Palomares I, Matarranz A, Martinez-Indart L, Ortiz de Urbina J. Intraoperative Portal Flow of Less Than 1 Liter per Minute After Orthotopic Liver Transplantation Is Not Associated Per Se With an Increased Rate of Early Graft Dysfunction. Transplant Proc 2017; 48:2495-2498. [PMID: 27742333 DOI: 10.1016/j.transproceed.2016.08.028] [Citation(s) in RCA: 5] [Impact Index Per Article: 0.7] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 12/12/2022]
Abstract
OBJECTIVE The aim of this study was to determine whether a portal flow of <1,000 mL/min in orthotopic liver transplantation (OLT) is associated with a higher incidence of early graft dysfunction (EGD) and graft loss. METHODS A retrospective study was performed of 540 OLTs carried out consecutively from December 2004 to December 2013. Patients were divided into 2 groups: group A, portal flow <1,000 mL/min; and group B, portal flow >1,000 mL/min. We studied the incidence of EGD and graft survival. A subanalysis was performed to define the minimum acceptable portal flow/100 g of liver weight to reduce the development EGD and graft loss. RESULTS Group A included 29 patients and group B, 511 patients. Group A had significantly lower-weight donors and recipients, female recipients with cholestatic disease, lower MELD scores, and lower hepatic artery flow. EGD occurred in 7 patients in group A (24.1%) versus 101 patients in group B (19.8%; P = .43). No significant differences were found in 1- and 5-year graft survival. A portal flow of <80 mL/min/100 g of liver weight was related to a significantly higher risk of developing EGD (odds ratio, 4.35; 95% confidence interval [CI], 1.46-12.91; P = .008) and graft loss (hazard ratio, 4.05; 95% CI, 1.32-12.42; P = .014). CONCLUSIONS Intraoperative portal flow of <1,000 mL/min in OLT was not related per se with a higher incidence of EGD or graft loss. Significantly higher risk of developing EGD and graft loss was associated with a portal flow of <80 mL/min/100 g of liver weight.
Collapse
Affiliation(s)
- M Gastaca
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain.
| | - M Prieto
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| | - A Valdivieso
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| | - P Ruiz
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| | - A Ventoso
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| | - I Palomares
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| | - A Matarranz
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| | - L Martinez-Indart
- Clinical Epidemiology Unit, Cruces University Hospital, Biocruces Health Research Institute, Bilbao, Spain
| | - J Ortiz de Urbina
- Hepatobiliary Surgery and Liver Transplantation Unit, Cruces University Hospital, University of the Basque Country, Bilbao, Spain
| |
Collapse
|
37
|
Perelló C, Carrión JA, Ruiz-Antorán B, Crespo J, Turnes J, Llaneras J, Lens S, Delgado M, García-Samaniego J, García-Paredes F, Fernández I, Morillas RM, Rincón D, Porres JC, Prieto M, Lázaro Ríos M, Fernández-Rodríguez C, Hermo JA, Rodríguez M, Herrero JI, Ruiz P, Fernández JR, Macías M, Pascasio JM, Moreno JM, Serra MÁ, Arenas J, Real Y, Jorquera F, Calleja JL. Effectiveness and safety of ombitasvir, paritaprevir, ritonavir ± dasabuvir ± ribavirin: An early access programme for Spanish patients with genotype 1/4 chronic hepatitis C virus infection. J Viral Hepat 2017; 24:226-237. [PMID: 27976491 DOI: 10.1111/jvh.12637] [Citation(s) in RCA: 17] [Impact Index Per Article: 2.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 07/26/2016] [Accepted: 10/11/2016] [Indexed: 12/16/2022]
Abstract
Over the last 5 years, therapies for hepatitis C virus (HCV) infection have improved significantly, achieving sustained virologic response (SVR) rates of up to 100% in clinical trials in patients with HCV genotype 1. We investigated the effectiveness and safety of ombitasvir/paritaprevir/ritonavir±dasabuvir in an early access programme. This was a retrospective, multicentre, national study that included 291 treatment-naïve and treatment-experienced patients with genotype 1 or 4 HCV infection. Most patients (65.3%) were male, and the mean age was 57.5 years. The mean baseline viral load was 6.1 log, 69.8% had HCV 1b genotype, 72.9% had cirrhosis and 34.7% were treatment-naïve. SVR at 12 weeks posttreatment was 96.2%. Four patients had virological failure (1.4%), one leading to discontinuation. There were no statistical differences in virological response according to genotype or liver fibrosis. Thirty patients experienced serious adverse events (SAEs) (10.3%), leading to discontinuation in six cases. Hepatic decompensation was observed in five patients. Four patients died during treatment or follow-up, three of them directly related to liver failure. Multivariate analyses showed a decreased probability of achieving SVR associated with baseline albumin, bilirubin and Child-Pugh score B, and a greater probability of developing SAEs related to age and albumin. This combined therapy was highly effective in clinical practice with an acceptable safety profile and low rates of treatment discontinuation.
Collapse
Affiliation(s)
- C Perelló
- Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, Madrid, Spain.,CIBERehd, Madrid, Spain
| | - J A Carrión
- Hospital del Mar, IMIM (Hospital del Mar Medical Research Institute), Barcelona, Spain.,Universitat Autonoma de Barcelona, Barcelona, Spain
| | - B Ruiz-Antorán
- Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, Madrid, Spain
| | - J Crespo
- Hospital Universitario Marqués de Valdecilla, IDIVAL, Santander, Spain.,Facultad de Medicina, Universidad de Cantabria, Santander, Spain
| | - J Turnes
- Complejo Hospitalario Universitario de Pontevedra and IISGS, Pontevedra, Spain
| | - J Llaneras
- Hospital Universitario Vall D'Hebrón, Barcelona, Spain
| | - S Lens
- CIBERehd, Madrid, Spain.,Hospital Clinic, IDIBAPS, Barcelona, Spain
| | - M Delgado
- Hospital Universitario A Coruña, A Coruña, Spain
| | | | | | - I Fernández
- Hospital Universitario Doce de Octubre, Madrid, Spain
| | - R M Morillas
- CIBERehd, Madrid, Spain.,Hospital Universitario Germans Trias i Pujol, Badalona, Spain
| | - D Rincón
- CIBERehd, Madrid, Spain.,Hospital General Universitario Gregorio Marañón, Madrid, Spain
| | - J C Porres
- Hospital Universitario Fundación Jiménez Díaz, Madrid, Spain
| | - M Prieto
- CIBERehd, Madrid, Spain.,Hospital Universitari i Politècnic La Fe, Valencia, Spain
| | - M Lázaro Ríos
- Hospital Universitario Miguel Servet, Zaragoza, Spain
| | | | - J A Hermo
- Hospital Álvaro Cunqueiro, Vigo, Spain
| | - M Rodríguez
- Hospital Universitario Central de Asturias, Oviedo, Spain
| | - J I Herrero
- CIBERehd, Madrid, Spain.,Clínica Universidad de Navarra, Instituto de Investigación Sanitaria de Navarra (IdiSNA), Pamplona, Spain
| | - P Ruiz
- Hospital Universitario Basurto, Bilbao, Spain
| | | | - M Macías
- Hospital Universitario Puerta del Mar, Cádiz, Spain
| | - J M Pascasio
- CIBERehd, Madrid, Spain.,Hospital Universitario Virgen del Rocío, Sevilla, Spain
| | - J M Moreno
- Complejo Hospitalario Albacete, Albacete, Spain
| | - M Á Serra
- Hospital Universitario Clínico Valencia, INCLIVA, Valencia, Spain.,University of Valencia, Valencia, Spain
| | - J Arenas
- Hospital Universitario Donostia, Donostia, Spain
| | - Y Real
- Hospital Universitario La Princesa, Madrid, Spain
| | - F Jorquera
- CIBERehd, Madrid, Spain.,Complejo Asistencial de León, IBIOMED, León, Spain
| | - J L Calleja
- Hospital Universitario Puerta de Hierro Majadahonda, IDIPHIM, Madrid, Spain.,CIBERehd, Madrid, Spain.,Universidad Autónoma de Madrid, Madrid, Spain
| | | |
Collapse
|
38
|
Gonzalez del Alba A, Puente J, Sala N, Mendez MJ, Pinto A, Rodriguez Sanchez A, Cuevas Sanz JM, Muñoz del Toro J, Ruiz P, Garcia A, Vazquez-Estevez S. Abiraterone acetate with prednisone and cabazitaxel as subsequent treatment after first-line docetaxel in metastatic castrate-resistant prostate cancer (mCRPC): Final efficacy and safety analysis of the CAPRO study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.6_suppl.276] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
276 Background: Abiraterone acetate + prednisone (AA) and cabazitaxel (CB) have shown an improvement in overall survival after Docetaxel (DOC) in (mCRPC)1,2. There is little evidence about the optimal sequencing treatment in prospective trials. In this final analysis we now compare the efficacy of AA and CB as second line (2L) treatment in mCRPC patients (pts) in routine clinical practice (RCP) in Spain. Methods: The CAPRO study is a prospective multicenter national observational descriptive study. The primary endpoint was to describe the management in 2L mCRPC pts after DOC in RCP. bPFS (biochemical progression free survival) and PFS (clinical or radiological progression free survival) were assessed by the Kaplan-Meier method. Results: 150 patients were recruited (Jul 2013-Jan 2015). At median follow-up of 7.8 mo (IQR 4.2-12.8) 67% (n = 100) of the pts received AA, 29% (n = 44) CB, and 4% (n = 6) other treatments as 2L. PSA response > 50% was 47.3% and 32.3% for AA group and CB group respectively (p = 0.146). Median bPFS was similar between the AA and the CB group (9.19 mo [95% CI 6.84-11.55] vs 9.92 mo [95% CI 6.08-13.76]; hazard ratio 0.779 [95% CI 0·49–1.24]; p = 0·29), whereas median PFS was significantly longer in the AA group than in the CB group (8.74 mo [95% CI 6.54-10.94] vs 6.41 mo [95% CI 4.99-7.82]; hazard ratio 0·56 [95% CI 0·38–0·85]; p = 0·005). A difference was observed in bPFS and PFS depending on the time of progression to first line (during treatment, < 3 or more than 3 mo) for both AA and CB. The most common toxicities of special interest (all grades/grade 3–4 as % of pts) were fatigue (31/1% in the AA group vs 54/4% in the CB group), oedema (15/0% AA group vs 13/4% CB group), hypertension 7/1% AA group, diarrhea (8/0% AA group vs 31/4% CB group), vomits (9/2% AA group vs 11/0 CB group) and neutropenia 7/4% CB group. Conclusions: In this final analysis AA was the 2L treatment of choice in routine clinical practice in Spain during the period of time in which the study was conducted. PSA response and bPFS were similar between AA and CB, whereas PFS was significantly longer in the AA group. There were no new safety signals observed.
Collapse
Affiliation(s)
| | - Javier Puente
- Hospital Clinico Universitario San Carlos, Madrid, Spain
| | - Nuria Sala
- Medical Oncology Department, Catalan Institute of Oncology-IDIBGi, Girona, Spain
| | | | | | | | | | | | - Pedro Ruiz
- Janssen-Cilag Medical Oncology Department, Madrid, Spain
| | | | | |
Collapse
|
39
|
Sala N, Méndez-Vidal MJ, Pinto A, Puente J, Rodriguez Sanchez A, Cuevas Sanz JM, Vazquez-Estevez S, Muñoz del Toro J, Ruiz P, Garcia A, Gonzalez del Alba A. Predictors of long-term response to abiraterone acetate with prednisone and cabazitaxel after first-line docetaxel in patients with metastastic castration-resistant prostate cancer (mCRPC): Subgroup analysis of a prospective observational study. J Clin Oncol 2017. [DOI: 10.1200/jco.2017.35.6_suppl.227] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/20/2022] Open
Abstract
227 Background: Recently treatment options for mCRPC have increased considerably. It remains unclear if there is any predictive factor to recognize which patients (pts) could obtain the most benefit in second line (2L) mCRPC. Recent data have been published addressing long-term predictive factors in a retrospective cohort in 2L1. We aim to reproduce it in this prospective study. Methods: The CAPRO study is a prospective multicenter national observational descriptive study. The primary endpoint was to describe the management in 2L mCRPC pts after DOC in routine clinical practice. To characterize which factors are associated with a better response in 2L mCRPC, we performed a multivariant analysis in the subgroup of pts with a long-term response (long-term responders (LTR): pts receiving abiraterone acetate + prednisone (AA) or Cabazitaxel (CB) for > 12 mo). Results: 150 patients were recruited (Jul 2013-Jan 2015). We identified 36 LTR (29/100 with AA: (29%) and 7/44 (15.9 %) with CB as 2L. No statistical differences in the number of LTR treated with AA vs CB (p = 0.095) were observed. LTR group (before starting 2L): median age 77.2 (51-87) median PSA 56.7 ng/dL (5.3-2627 ng/dL), alkaline phosphatase 92.5 IU/L (44-630 IU/L) and LDH 221.5 IU/L (147-445 IU/L). At median follow-up of 7.8 mo (IQR 4.2- 12.8), median PFS (clinical and/or radiological) was significantly longer in LTR AA group (not yet reached) vs LTR CB group 18.14 [95% CI 12.67-23.6]; HR 0·29 [95% CI 0,092 – 0,918; p = 0.025]. In a multivariate analysis two factors were significantly associated with LTR in 2L mCRPC: Gleason score < 7 (OR: 0.22 95% CI 0.065-0.745, p = 0.015) and normal LDH ( < 250 IU/L) (OR: 0.235, 95% CI 0.093-0.595, p = 0.002). No differences in safety profile between LTR vs non LTR of AA group and CB group were found. Conclusions: In this final subgroup analysis we observed Gleason score < 7 and LDH < 250 IU/L are predictors of long term response in 2L mCRPC. Median PFS in LTR treated with AA was significantly longer than LTR treated with CB. These findings need to be validated in further larger prospective studies.
Collapse
Affiliation(s)
- Nuria Sala
- Medical Oncology Department, Catalan Institute of Oncology-IDIBGi, Girona, Spain
| | | | | | - Javier Puente
- Hospital Clinico Universitario San Carlos, Madrid, Spain
| | | | | | | | | | - Pedro Ruiz
- Janssen-Cilag Medical Oncology Department, Madrid, Spain
| | | | | |
Collapse
|
40
|
Lewis-Fernández R, Rotheram-Borus MJ, Trotter Betts V, Greenman L, M. Essock S, I. Escobar J, Barch D, F. Hogan M, Areàn PA, Druss BG, DiClemente RJ, McGlashan TH, Jeste DV, Proctor EK, Ruiz P, Rush AJ, Canino GJ, Bell CC, Henry R, Iversen P. Dibattiti. Ripensare le priorità nei finanziamenti della ricerca sulla salute mentale. PSICOTERAPIA E SCIENZE UMANE 2017. [DOI: 10.3280/pu2017-001007] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/19/2022]
|
41
|
Viñals F, Ruiz P, Correa F, Gonçalves Pereira P. Two-dimensional visualization and measurement of the fetal optic chiasm: improving counseling for antenatal diagnosis of agenesis of the septum pellucidum. Ultrasound Obstet Gynecol 2016; 48:733-738. [PMID: 26776289 DOI: 10.1002/uog.15862] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Subscribe] [Scholar Register] [Received: 11/24/2015] [Revised: 12/25/2015] [Accepted: 01/08/2016] [Indexed: 06/05/2023]
Abstract
OBJECTIVE To develop an objective method for visualizing and measuring the fetal optic chiasm (OC) using transvaginal two-dimensional (2D) ultrasound in the coronal plane and to report measurements in fetuses with agenesis of the septum pellucidum (SP). METHODS This was a prospective cross-sectional study of 115 morphologically normal fetuses in low-risk pregnancies, between 21 and 30 weeks' gestation. The OC was measured in a coronal plane at the level of the third ventricle and was seen as a horizontally aligned dumbbell-shaped structure of moderate echogenicity. In addition, OC measurements from eight fetuses with agenesis of the SP and complete follow-up were compared with the reference range. RESULTS OC measurements were obtained in 110/115 normal fetuses and showed that OC increases linearly with gestational age. Our method of measurement demonstrated good intraobserver repeatability and excellent interobserver reproducibility. Among the eight fetuses with agenesis of the SP, five had normal OC measurements and five had normal vision postnatally. Pregnancy continued to term in all cases and the follow-up period varied from 6 months to 7 years. CONCLUSION Our study demonstrates that it is possible to visualize and measure the OC directly on a 2D ultrasound coronal plane. In fetuses with agenesis of the SP, the morphology and width of the OC visual pathway could prove a relevant tool for assessing its development. It would also help in the difficult task of providing antenatal counseling when faced with the diagnosis of agenesis of the SP. Copyright © 2016 ISUOG. Published by John Wiley & Sons Ltd.
Collapse
Affiliation(s)
- F Viñals
- Centro AGB Ultrasonografía, Clínica Sanatorio Alemán and Facultad de Medicina, Universidad de Concepción, Concepción, Chile
| | - P Ruiz
- Centro AGB Ultrasonografía, Clínica Sanatorio Alemán and Facultad de Medicina, Universidad de Concepción, Concepción, Chile
- Hospital Costa del Sol, Marbella, Spain
| | - F Correa
- Fetal and Neonatal Ultrasound Department, Hospital Fernando Fonseca, Lisbon, Portugal
| | | |
Collapse
|
42
|
Demetris AJ, Bellamy C, Hübscher SG, O'Leary J, Randhawa PS, Feng S, Neil D, Colvin RB, McCaughan G, Fung JJ, Del Bello A, Reinholt FP, Haga H, Adeyi O, Czaja AJ, Schiano T, Fiel MI, Smith ML, Sebagh M, Tanigawa RY, Yilmaz F, Alexander G, Baiocchi L, Balasubramanian M, Batal I, Bhan AK, Bucuvalas J, Cerski CTS, Charlotte F, de Vera ME, ElMonayeri M, Fontes P, Furth EE, Gouw ASH, Hafezi-Bakhtiari S, Hart J, Honsova E, Ismail W, Itoh T, Jhala NC, Khettry U, Klintmalm GB, Knechtle S, Koshiba T, Kozlowski T, Lassman CR, Lerut J, Levitsky J, Licini L, Liotta R, Mazariegos G, Minervini MI, Misdraji J, Mohanakumar T, Mölne J, Nasser I, Neuberger J, O'Neil M, Pappo O, Petrovic L, Ruiz P, Sağol Ö, Sanchez Fueyo A, Sasatomi E, Shaked A, Shiller M, Shimizu T, Sis B, Sonzogni A, Stevenson HL, Thung SN, Tisone G, Tsamandas AC, Wernerson A, Wu T, Zeevi A, Zen Y. 2016 Comprehensive Update of the Banff Working Group on Liver Allograft Pathology: Introduction of Antibody-Mediated Rejection. Am J Transplant 2016; 16:2816-2835. [PMID: 27273869 DOI: 10.1111/ajt.13909] [Citation(s) in RCA: 361] [Impact Index Per Article: 45.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 05/06/2016] [Revised: 06/01/2016] [Accepted: 05/25/2016] [Indexed: 02/06/2023]
Abstract
The Banff Working Group on Liver Allograft Pathology reviewed and discussed literature evidence regarding antibody-mediated liver allograft rejection at the 11th (Paris, France, June 5-10, 2011), 12th (Comandatuba, Brazil, August 19-23, 2013), and 13th (Vancouver, British Columbia, Canada, October 5-10, 2015) meetings of the Banff Conference on Allograft Pathology. Discussion continued online. The primary goal was to introduce guidelines and consensus criteria for the diagnosis of liver allograft antibody-mediated rejection and provide a comprehensive update of all Banff Schema recommendations. Included are new recommendations for complement component 4d tissue staining and interpretation, staging liver allograft fibrosis, and findings related to immunosuppression minimization. In an effort to create a single reference document, previous unchanged criteria are also included.
Collapse
Affiliation(s)
- A J Demetris
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - C Bellamy
- The University of Edinburgh, Edinburgh, Scotland
| | | | - J O'Leary
- Baylor University Medical Center, Dallas, TX
| | - P S Randhawa
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - S Feng
- University of California San Francisco Medical Center, San Francisco, CA
| | - D Neil
- Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - R B Colvin
- Massachusetts General Hospital, Boston, MA
| | - G McCaughan
- Royal Prince Alfred Hospital, Sydney, Australia
| | | | | | - F P Reinholt
- Oslo University Hospital Rikshospitalet, Oslo, Norway
| | - H Haga
- Kyoto University Hospital, Kyoto, Japan
| | - O Adeyi
- University Health Network and University of Toronto, Toronto, Canada
| | - A J Czaja
- Mayo Clinic College of Medicine, Rochester, MN
| | - T Schiano
- Mount Sinai Medical Center, New York, NY
| | - M I Fiel
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - M L Smith
- Mayo Clinic Health System, Scottsdale, AZ
| | - M Sebagh
- AP-HP Hôpital Paul-Brousse, Paris, France
| | - R Y Tanigawa
- Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
| | - F Yilmaz
- University of Ege, Faculty of Medicine, Izmir, Turkey
| | | | - L Baiocchi
- Policlinico Universitario Tor Vergata, Rome, Italy
| | | | - I Batal
- Columbia University College of Physicians and Surgeons, New York, NY
| | - A K Bhan
- Massachusetts General Hospital, Boston, MA
| | - J Bucuvalas
- Cincinnati Children's Hospital Medical Center, Cincinnati, OH
| | - C T S Cerski
- Universidade Federal do Rio Grande do Sul, Hospital de Clinicas de Porto Alegre, Porto Alegre, Brazil
| | | | | | - M ElMonayeri
- Ain Shams University, Wady El-Neel Hospital, Cairo, Egypt
| | - P Fontes
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - E E Furth
- Hospital of the University of Pennsylvania, Philadelphia, PA
| | - A S H Gouw
- University Medical Center Groningen, Groningen, the Netherlands
| | | | - J Hart
- University of Chicago Hospitals, Chicago, IL
| | - E Honsova
- Institute for Clinical and Experimental Medicine, Prague, Czech Republic
| | - W Ismail
- Beni-Suef University, Beni-Suef, Egypt
| | - T Itoh
- Kobe University Hospital, Kobe, Japan
| | | | - U Khettry
- Lahey Hospital and Medical Center, Burlington, MA
| | | | - S Knechtle
- Duke University Health System, Durham, NC
| | - T Koshiba
- Soma Central Hospital, Soma, Fukushima, Japan
| | - T Kozlowski
- University of North Carolina at Chapel Hill, Chapel Hill, NC
| | - C R Lassman
- David Geffen School of Medicine at UCLA, Los Angeles, CA
| | - J Lerut
- Cliniques Universitaires Saint-Luc, Brussels, Belgium
| | - J Levitsky
- Northwestern University Feinberg School of Medicine, Chicago, IL
| | - L Licini
- Pope John XXIII Hospital, Bergamo, Italy
| | - R Liotta
- Istituto di Ricovero e Cura a Carattere Scientifico, Istituto Mediterraneo per i Trapianti e Terapie ad Alta Specializzazione, University of Pittsburgh Medical Center, Palermo, Italy
| | - G Mazariegos
- Children's Hospital of Pittsburgh of University of Pittsburgh Medical Center, Pittsburgh, PA
| | - M I Minervini
- University of Pittsburgh Medical Center, Pittsburgh, PA
| | - J Misdraji
- Massachusetts General Hospital, Boston, MA
| | - T Mohanakumar
- St. Joseph's Hospital and Medical Center, Norton Thoracic Institute, Phoenix, AZ
| | - J Mölne
- University of Gothenburg, Sahlgrenska University Hospital, Gothenburg, Sweden
| | - I Nasser
- Harvard Medical School, Beth Israel Deaconess Medical Center, Boston, MA
| | - J Neuberger
- Queen Elizabeth Hospital Birmingham, Birmingham, UK
| | - M O'Neil
- University of Kansas Medical Center, Kansas City, KS
| | - O Pappo
- Hadassah Medical Center, Jerusalem, Israel
| | - L Petrovic
- University of Southern California, Los Angeles, CA
| | - P Ruiz
- University of Miami, Miami, FL
| | - Ö Sağol
- School of Medicine, Dokuz Eylul University, Izmir, Turkey
| | | | - E Sasatomi
- University of North Carolina School of Medicine, Chapel Hill, NC
| | - A Shaked
- University of Pennsylvania Health System, Philadelphia, PA
| | - M Shiller
- Baylor University Medical Center, Dallas, TX
| | - T Shimizu
- Toda Chuo General Hospital, Saitama, Japan
| | - B Sis
- University of Alberta Hospital, Edmonton, Canada
| | - A Sonzogni
- Pope John XXIII Hospital, Bergamo, Italy
| | | | - S N Thung
- Icahn School of Medicine at Mount Sinai, New York, NY
| | - G Tisone
- University of Rome-Tor Vergata, Rome, Italy
| | | | - A Wernerson
- Karolinska University Hospital, Stockholm, Sweden
| | - T Wu
- Tulane University School of Medicine, New Orleans, LA
| | - A Zeevi
- University of Pittsburgh, Pittsburgh, PA
| | - Y Zen
- Kobe University Hospital, Kobe, Japan
| |
Collapse
|
43
|
Causse M, Ruiz P, Gutierrez JB, Vaquero M, Casal M. New Anyplex™ II MTB/MDR/XDR kit for detection of resistance mutations in M. tuberculosis cultures. Int J Tuberc Lung Dis 2016; 19:1542-6. [PMID: 26614199 DOI: 10.5588/ijtld.15.0235] [Citation(s) in RCA: 9] [Impact Index Per Article: 1.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/10/2022] Open
Abstract
SETTINGS The new Anyplex™ II MTB/MDR/XDR PCR assay enables the joint analysis of mutations conferring resistance to first- and second-line anti-tuberculosis drugs and the detection of Mycobacterium tuberculosis. OBJECTIVES To evaluate the performance of the new Anyplex assay in detecting mutations that confer resistance to first- and second-line drugs in M. tuberculosis cultures. DESIGN Results obtained using the new technique were compared with those obtained by phenotypic drug susceptibility testing (DST) and with two GenoType tests for the detection of mutations: GenoType(®) MTBDRplus and GenoType(®) MTBDRsl. RESULTS For rifampicin resistance mutations, Anyplex displayed 97% sensitivity and 100% specificity compared with 100% and 100% for MTBDRplus. For isoniazid (INH) resistance, Anyplex displayed 61% sensitivity and 98% specificity compared with 62% and 98% for MTBDRplus. For second-line drugs, Anyplex recorded 95% sensitivity and 99% specificity in the detection of resistance to quinolones compared with 100% and 98% for the MTBDRsl. While both techniques displayed 100% specificity for aminoglycoside resistance mutations, sensitivity was 100% for Anyplex and 88% for MTBDRsl. CONCLUSIONS Results obtained using Anyplex agreed strongly with those obtained using the two GenoType molecular techniques and with phenotypic DST, except in the case of INH, due to the large number of genes involved in resistance to this drug.
Collapse
Affiliation(s)
- M Causse
- Microbiology Service, Reina Sofía University Hospital, Córdoba, Spain
| | - P Ruiz
- Mycobacteria Reference Center, Department of Microbiology, Faculty of Medicine, University of Córdoba, Córdoba, Spain
| | - J B Gutierrez
- Microbiology Service, Reina Sofía University Hospital, Córdoba, Spain
| | - M Vaquero
- Mycobacteria Reference Center, Department of Microbiology, Faculty of Medicine, University of Córdoba, Córdoba, Spain
| | - M Casal
- Microbiology Service, Reina Sofía University Hospital, Córdoba, Spain; Mycobacteria Reference Center, Department of Microbiology, Faculty of Medicine, University of Córdoba, Córdoba, Spain
| |
Collapse
|
44
|
|
45
|
Suarez JF, Rosa R, Lorio MA, Morris MI, Abbo LM, Simkins J, Guerra G, Roth D, Kupin WL, Mattiazzi A, Ciancio G, Chen LJ, Burke GW, Goldstein MJ, Ruiz P, Camargo JF. Pretransplant CD4 Count Influences Immune Reconstitution and Risk of Infectious Complications in Human Immunodeficiency Virus-Infected Kidney Allograft Recipients. Am J Transplant 2016; 16:2463-72. [PMID: 26953224 PMCID: PMC4956530 DOI: 10.1111/ajt.13782] [Citation(s) in RCA: 30] [Impact Index Per Article: 3.8] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/05/2015] [Revised: 02/25/2016] [Accepted: 02/27/2016] [Indexed: 01/25/2023]
Abstract
In current practice, human immunodeficiency virus-infected (HIV(+) ) candidates with CD4 >200 cells/mm(3) are eligible for kidney transplantation; however, the optimal pretransplant CD4 count above this threshold remains to be defined. We evaluated clinical outcomes in patients with baseline CD4 >350 and <350 cells/mm(3) among 38 anti-thymocyte globulin (ATG)-treated HIV-negative to HIV(+) kidney transplants performed at our center between 2006 and 2013. Median follow-up was 2.6 years. Rates of acute rejection and patient and graft survival were not different between groups. Occurrence of severe CD4 lymphopenia (<200 cells/mm(3) ), however, was more common among patients with a baseline CD4 count 200-349 cells/mm(3) compared with those transplanted at higher counts (75% vs. 30% at 4 weeks [p = 0.04] and 71% vs. 5% at 52 weeks [p = 0.001], respectively, after transplant). After adjusting for age, baseline CD4 count of 200-349 cells/mm(3) was an independent predictor of severe CD4 lymphopenia at 4 weeks (relative risk [RR] 2.6; 95% confidence interval [CI] 1.3-5.1) and 52 weeks (RR 14.3; 95% CI 2-100.4) after transplant. Patients with CD4 <200 cells/mm(3) at 4 weeks had higher probability of serious infections during first 6 months after transplant (19% vs. 50%; log-rank p = 0.05). These findings suggest that ATG must be used with caution in HIV(+) kidney allograft recipients with a pretransplant CD4 count <350 cells/mm(3) .
Collapse
Affiliation(s)
- J. F. Suarez
- Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - R. Rosa
- Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA
| | - M. A. Lorio
- Department of Medicine, University of Miami Miller School of Medicine, Miami, FL, USA
| | - M. I. Morris
- Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA
| | - L. M. Abbo
- Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA
| | - J. Simkins
- Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA
| | - G. Guerra
- Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - D. Roth
- Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - W. L. Kupin
- Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - A. Mattiazzi
- Department of Medicine, Division of Nephrology, University of Miami Miller School of Medicine, Miami, FL, USA
| | - G. Ciancio
- Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute at the Jackson Memorial Hospital, Miami, FL, USA
| | - L. J. Chen
- Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute at the Jackson Memorial Hospital, Miami, FL, USA
| | - G. W. Burke
- Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute at the Jackson Memorial Hospital, Miami, FL, USA
| | - M. J. Goldstein
- Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute at the Jackson Memorial Hospital, Miami, FL, USA
| | - P. Ruiz
- Department of Surgery, University of Miami Miller School of Medicine and Miami Transplant Institute at the Jackson Memorial Hospital, Miami, FL, USA
| | - J. F. Camargo
- Department of Medicine, Division of Infectious Diseases, University of Miami Miller School of Medicine, Miami, FL, USA,Corresponding author: Jose F Camargo, MD, Division of Infectious Diseases, University of Miami Health System. 1120 NW 14 Street, Miami, FL 33136. Phone: 305-243-4598, Fax: 305-243-4037.
| |
Collapse
|
46
|
Abstract
Verbal communication is essential to psychiatry, and language is its indispensable tool. Neurological, emotional, behavioral, intellectual and cultural factors are intrinsically involved in the use of language competence and preference, native tongue and bilingualism. Language also influences one's own understanding of health and illness. Reframing the "minority" concept so that Hispanics can be perceived as a linguo-cultural minority can, undoubtedly, help considerably in the understanding of the problems faced by the Hispanic populations in the United States. Linguo-cultural discrimination leads to undereducation, underemployment and limited economic success. Further linguo-cultural barriers leads to underutilization of services, diagnostic errors and poor treatment. This paper addresses all these issues, and attempts to present solutions and guidelines for further research in this area.
Collapse
|
47
|
Ciancio G, Tryphonopoulos P, Gaynor J, Guerra G, Sageshima J, Roth D, Chen L, Kupin W, Mattiazzi A, Tueros L, Flores S, Hanson L, Powell R, Ruiz P, Vianna R, Burke G. Pilot Randomized Trial of Tacrolimus/Everolimus vs Tacrolimus/Enteric-Coated Mycophenolate Sodium in Adult, Primary Kidney Transplant Recipients at a Single Center. Transplant Proc 2016; 48:2006-10. [DOI: 10.1016/j.transproceed.2016.03.048] [Citation(s) in RCA: 3] [Impact Index Per Article: 0.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 12/16/2015] [Revised: 02/19/2016] [Accepted: 03/01/2016] [Indexed: 10/21/2022]
|
48
|
Lewis-Fernández R, Rotheram-Borus MJ, Betts VT, Greenman L, Essock SM, Escobar JI, Barch D, Hogan MF, Areán PA, Druss BG, DiClemente RJ, McGlashan TH, Jeste DV, Proctor EK, Ruiz P, Rush AJ, Canino GJ, Bell CC, Henry R, Iversen P. Rethinking funding priorities in mental health research. Br J Psychiatry 2016; 208:507-9. [PMID: 27251688 DOI: 10.1192/bjp.bp.115.179895] [Citation(s) in RCA: 26] [Impact Index Per Article: 3.3] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Received: 12/10/2015] [Accepted: 03/29/2016] [Indexed: 11/23/2022]
Abstract
Mental health research funding priorities in high-income countries must balance longer-term investment in identifying neurobiological mechanisms of disease with shorter-term funding of novel prevention and treatment strategies to alleviate the current burden of mental illness. Prioritising one area of science over others risks reduced returns on the entire scientific portfolio.
Collapse
Affiliation(s)
- Roberto Lewis-Fernández
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Mary Jane Rotheram-Borus
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Virginia Trotter Betts
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Lisa Greenman
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Susan M Essock
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Javier I Escobar
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Deanna Barch
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Michael F Hogan
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Patricia A Areán
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Benjamin G Druss
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Ralph J DiClemente
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Thomas H McGlashan
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Dilip V Jeste
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Enola K Proctor
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Pedro Ruiz
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - A John Rush
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Glorisa J Canino
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Carl C Bell
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Renata Henry
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| | - Portia Iversen
- Roberto Lewis-Fernández, MD, Columbia University Medical Center, and New York State Center of Excellence for Cultural Competence, and Hispanic Treatment Program, at the New York State Psychiatric Institute, New York, USA; Mary Jane Rotheram-Borus, PhD, Department of Psychiatry and Biobehavioral Sciences, Semel Institute, University of California at Los Angeles, Los Angeles, California, USA; Virginia Trotter Betts, MSN, JD, RN, HealthFutures, Inc., Nashville, Tennessee, USA; Lisa Greenman, JD, Attorney At Law, Washington, DC, USA; Susan M. Essock, PhD, Columbia University Medical Center, New York, USA; Javier I. Escobar, MD, Rutgers-Robert Wood Johnson Medical School, New Brunswick, New Jersey, USA; Deanna Barch, PhD, Washington University in St Louis, St Louis, Missouri, USA; Michael F. Hogan, PhD, Dartmouth (Geisinger) Medical School, Case Western Reserve Medical School, and New York University Medical School, and Hogan Health Solutions, New York, USA; Patricia A. Areán, PhD, Department of Psychiatry and Behavioral Sciences, University of Washington, Seattle, Washington, USA; Benjamin G. Druss, MD, MPH, Ralph J. DiClemente, PhD, Rollins School of Public Health, Emory University, Atlanta, Georgia, USA; Thomas H. McGlashan, MD, Yale University School of Medicine, and Connecticut Mental Health Center, New Haven, Connecticut, USA; Dilip V. Jeste, MD, Sam and Rose Stein Institute for Research on Aging, University of California San Diego, San Diego, California, USA; Enola K. Proctor, PhD, Brown School of Social Work, and Center for Mental Health Services Research, Washington University in St Louis, St Louis, Missouri, USA; Pedro Ruiz, MD, Department of Psychiatry & Behavioral Sciences, Miller School of Medicine, University of Miami, Miami, Florida, USA; A. John Rush, MD, Duke-National University of Singapore, and Duke Medical School, Santa Fe, New Mexico, USA; Glorisa J. Canino, PhD, Behavioral Sciences Research Institute, and Department of Pediatrics, University of Pu
| |
Collapse
|
49
|
Crespo G, Gambato M, Millán O, Casals G, Ruiz P, Londoño MC, Mira A, Forns X, Brunet M, Jiménez W, Navasa M. Early non-invasive selection of patients at high risk of severe hepatitis C recurrence after liver transplantation. Transpl Infect Dis 2016; 18:471-9. [PMID: 26992003 DOI: 10.1111/tid.12526] [Citation(s) in RCA: 11] [Impact Index Per Article: 1.4] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 07/07/2015] [Revised: 12/04/2015] [Accepted: 01/20/2016] [Indexed: 01/10/2023]
Abstract
BACKGROUND The early identification of patients at high risk of severe post liver transplant hepatitis C recurrence is relevant, as these patients may be treated using interferon (IFN)-free regimens. METHODS In a retrospective study with prospectively collected data, we investigated whether the use of several non-invasive methods (fibrosis 4 index [FIB-4], AST-to-platelets ratio index [APRI], enhanced liver fibrosis test [ELF], IFN-γ-inducible protein 10 [IP-10], and transient elastography by Fibroscan) and their combinations 6 months after transplantation could identify those recipients at higher risk of severe recurrence, defined by the presence of significant fibrosis (F ≥2) and/or portal hypertension (hepatic venous pressure gradient ≥6 mmHg) 12 months after transplant. Seventy-two hepatitis C virus (HCV)-infected liver transplant patients and 10 recipients in whom HCV was eradicated before transplantation were included in the study. RESULTS The levels of all biomarkers were significantly higher in HCV-infected recipients than in controls. Among HCV recipients, levels of biomarkers were significantly higher in patients with severe recurrence. Although there were no statistically significant differences between biomarkers, APRI, ELF, and FIB-4 obtained the highest area under the ROC curve values. The combination of serum biomarkers with Fibroscan increased the negative and positive predictive values, although diagnostic accuracy of individual tests was not significantly improved. CONCLUSIONS Patients at higher risk of severe HCV recurrence can be identified early, 6 months after transplantation, using readily available non-invasive methods.
Collapse
Affiliation(s)
- G Crespo
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M Gambato
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - O Millán
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - G Casals
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - P Ruiz
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M C Londoño
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - A Mira
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - X Forns
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M Brunet
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - W Jiménez
- Department of Biochemistry and Molecular Genetics, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| | - M Navasa
- Liver Unit, Hospital Clinic, IDIBAPS and CIBERehd, University of Barcelona, Barcelona, Spain
| |
Collapse
|
50
|
Río P, Navarro S, Guenechea G, Galy A, Sánchez R, Lamana ML, Yañez R, Casado JA, Segovia JC, Surrallés J, López R, de Andoaín NG, Ruiz P, Catalá A, de Heredia CD, Sevilla J, Bueren JA. 753. Lentiviral-Mediated Gene Correction of Mobilized Peripheral Blood Progenitors and Repopulating Cells from FA-A Patients. Mol Ther 2016. [DOI: 10.1016/s1525-0016(16)33561-4] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/20/2022] Open
|